Massimo Volpe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7009639/publications.pdf

Version: 2024-02-01

		7551	3173
813	43,000	77	186
papers	citations	h-index	g-index

845	845	845	44284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
3	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & amp; Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
4	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
5	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. European Heart Journal, 2020, 41, 2083-2088.	1.0	716
6	High Glucose Causes Upregulation of Cyclooxygenase-2 and Alters Prostanoid Profile in Human Endothelial Cells. Circulation, 2003, 107, 1017-1023.	1.6	389
7	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 40-51.	2.0	357
8	Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease. Circulation Research, 2014, 114, 549-564.	2.0	352
9	Acute Anti-Ischemic Effect of Testosterone in Men With Coronary Artery Disease. Circulation, 1999, 99, 1666-1670.	1.6	348
10	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	1.3	330
11	Deletion of p66 shc Gene Protects Against Age-Related Endothelial Dysfunction. Circulation, 2004, 110, 2889-2895.	1.6	276
12	Rheb is a Critical Regulator of Autophagy During Myocardial Ischemia. Circulation, 2012, 125, 1134-1146.	1.6	257
13	Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nature Genetics, 1996, 13, 429-434.	9.4	237
14	Insulin-Like Growth Factor-1 as a Vascular Protective Factor. Circulation, 2004, 110, 2260-2265.	1.6	231
15	Genetic deletion of p66Shc adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5217-5222.	3.3	229
16	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. European Heart Journal, 2013, 34, 2149-2157.	1.0	225
17	Natriuretic peptides in cardiovascular diseases: current use and perspectives. European Heart Journal, 2014, 35, 419-425.	1.0	221
18	Gene Silencing of the Mitochondrial Adaptor p66 ^{Shc} Suppresses Vascular Hyperglycemic Memory in Diabetes. Circulation Research, 2012, 111, 278-289.	2.0	219

#	Article	IF	Citations
19	Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension.. Journal of Clinical Investigation, 1992, 90, 24-29.	3.9	217
20	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clinical Science, 2015, 130, 57-77.	1.8	208
21	Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction. Journal of the American College of Cardiology, 2018, 71, 1999-2010.	1.2	195
22	Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. Journal of Human Hypertension, 2014, 28, 74-79.	1.0	192
23	Differential Roles of GSK-3Î² During Myocardial Ischemia and Ischemia/Reperfusion. Circulation Research, 2011, 109, 502-511.	2.0	185
24	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	1.3	177
25	Natriuretic Peptides: An Update on Bioactivity, Potential Therapeutic Use, and Implication in Cardiovascular Diseases. American Journal of Hypertension, 2008, 21, 733-741.	1.0	175
26	Current Situation of Medication Adherence in Hypertension. Frontiers in Pharmacology, 2017, 8, 100.	1.6	173
27	An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovascular Research, 2017, 113, 378-388.	1.8	164
28	Activation of NADPH Oxidase 4 in the Endoplasmic Reticulum Promotes Cardiomyocyte Autophagy and Survival During Energy Stress Through the Protein Kinase RNA-Activated-Like Endoplasmic Reticulum Kinase/Eukaryotic Initiation Factor 2Î±/Activating Transcription Factor 4 Pathway. Circulation Research, 2013, 113, 1253-1264.	2.0	162
29	Reactive Oxygen Species Mediate Endothelium-Dependent Relaxations in Tetrahydrobiopterin-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 496-502.	1.1	158
30	MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart, 2013, 99, 491-496.	1.2	157
31	Final Common Molecular Pathways of Aging and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 622-628.	1.1	155
32	Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. Journal of Hypertension, 2007, 25, 1035-1040.	0.3	144
33	Adverse Epigenetic Signatures by Histone Methyltransferase Set7 Contribute to Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Genetics, 2015, 8, 150-158.	5.1	141
34	Arterial stiffness is an independent risk factor for cognitive impairment in the elderly: a pilot study. Journal of Hypertension, 2005, 23, 1211-1216.	0.3	139
35	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels. Diabetes, 2017, 66, 2472-2482.	0.3	139
36	Association of Atrial Natriuretic Peptide and Type A Natriuretic Peptide Receptor Gene Polymorphisms With Left Ventricular Mass in Human Essential Hypertension. Journal of the American College of Cardiology, 2006, 48, 499-505.	1.2	137

#	Article	IF	Citations
37	Antihypertensive Treatment and Development of Heart Failure in Hypertension. Archives of Internal Medicine, 2011, 171, 384-94.	4.3	134
38	A New Electrocardiographic Marker of Sudden Death in Brugada Syndrome. Journal of the American College of Cardiology, 2016, 67, 1427-1440.	1.2	133
39	Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats.. Hypertension, 1990, 15, 318-326.	1.3	132
40	Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. American Journal of Cardiology, 1994, 74, 468-473.	0.7	132
41	Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart, 2007, 94, 487-492.	1.2	128
42	Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients. Hypertension, 2007, 49, 341-346.	1.3	125
43	Assessment of flow-mediated dilation reproducibility. Journal of Hypertension, 2012, 30, 1399-1405.	0.3	125
44	Role of the reninâ€“angiotensinâ€“aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clinical Science, 2009, 116, 467-477.	1.8	122
45	Selective Inhibition of Protein Kinase Cî² 2 Prevents Acute Effects of High Glucose on Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. Circulation, 2004, 110, 91-96.	1.6	120
46	Blood pressure control in Italy: results of recent surveys on hypertension. Journal of Hypertension, 2007, 25, 1491-1498.	0.3	117
47	Vascular Inflammation and Endothelial Dysfunction in Experimental Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	115
48	mTORC2 Regulates Cardiac Response to Stress by Inhibiting MST1. Cell Reports, 2015, 11, 125-136.	2.9	110
49	Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. American Journal of Hypertension, 2005, 18, 493-499.	1.0	107
50	Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. Journal of Human Hypertension, 2010, 24, 336-344.	1.0	106
51	Population-level changes to promote cardiovascular health. European Journal of Preventive Cardiology, 2013, 20, 409-421.	0.8	106
52	Atrial Natriuretic Peptide Gene Polymorphisms and Risk of Ischemic Stroke in Humans. Stroke, 2004, 35, 814-818.	1.0	105
53	Development of heart failure in recent hypertension trials. Journal of Hypertension, 2008, 26, 1477-1486.	0.3	105
54	Natriuretic peptides and cardio-renal disease. International Journal of Cardiology, 2014, 176, 630-639.	0.8	102

#	Article	IF	Citations
55	SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory. Diabetes, 2013, 62, 1800-1807.	0.3	96
56	Pathogenesis of Target Organ Damage in Hypertension: Role of Mitochondrial Oxidative Stress. International Journal of Molecular Sciences, 2015, 16, 823-839.	1.8	95
57	Tumor necrosis factor-Î± as trigger of platelet activation in patients with heart failure. Blood, 2005, 106, 1992-1994.	0.6	94
58	Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure.. Circulation, 1993, 88, 1620-1627.	1.6	93
59	Markers of Inflammation and Fibrosis Are Related to Cardiovascular Damage in Hypertensive Patients with Metabolic Syndrome. American Journal of Hypertension, 2007, 20, 784-791.	1.0	93
60	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	93
61	Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs.. Hypertension, 1986, 8, 312-316.	1.3	92
62	The Gene Encoding Atrial Natriuretic Peptide and the Risk of Human Stroke. Circulation, 1999, 100, 1722-1726.	1.6	92
63	New Insights into the Role of Mitochondrial Dynamics and Autophagy during Oxidative Stress and Aging in the Heart. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-13.	1.9	92
64	Deletion of the Activated Protein-1 Transcription Factor JunD Induces Oxidative Stress and Accelerates Age-Related Endothelial Dysfunction. Circulation, 2013, 127, 1229-1240.	1.6	90
65	Angiotensin II AT2 receptor subtype. Journal of Hypertension, 2003, 21, 1429-1443.	0.3	89
66	Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Frontiers in Medicine, 2021, 8, 798958.	1.2	88
67	Salt-regulating hormones in young normotensive obese subjects. Effects of saline load.. Hypertension, 1994, 23, I20-4.	1.3	87
68	The Renin-Angiotensin System as a Risk Factor and Therapeutic Target for Cardiovascular and Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, S173-S178.	3.0	87
69	Antiplatelet/Anticoagulant Agents and Chronic Subdural Hematoma in the Elderly. PLoS ONE, 2013, 8, e68732.	1.1	87
70	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. Journal of Hypertension, 2012, 30, 1056-1064.	0.3	86
71	Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. American Heart Journal, 1999, 138, 273-284.	1.2	85
72	Efficacy and Tolerability of Olmesartan Medoxomil Combined with Amlodipine in Patients with Moderate to Severe Hypertension after Amlodipine Monotherapy. Clinical Drug Investigation, 2009, 29, 11-25.	1.1	83

#	Article	IF	Citations
73	Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats.. Journal of Clinical Investigation, 1996, 98, 256-261.	3.9	82
74	Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.. Journal of Clinical Investigation, 1991, 88, 1481-1489.	3.9	81
75	Transcatheter Closure of Post-myocardial Infarction Ventricular Septal Rupture. Circulation: Cardiovascular Interventions, 2013, 6, 59-67.	1.4	80
76	A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients. Journal of Clinical Hypertension, 2010, 12, 666-677.	1.0	79
77	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. American Journal of Hypertension, 2011, 24, 582-590.	1.0	78
78	Blood pressure control in Italy. Journal of Hypertension, 2012, 30, 1065-1074.	0.3	78
79	Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. Journal of Hypertension, 2005, 23, 1575-1581.	0.3	77
80	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. Journal of Hypertension, 2007, 25, 2317-2324.	0.3	77
81	Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. International Journal of Cardiology, 2012, 157, 160-168.	0.8	76
82	Right Ventricular Dysfunction in Patients with End-Stage Renal Disease. American Journal of Nephrology, 2010, 32, 432-438.	1.4	75
83	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. European Heart Journal, 2015, 36, 817-828.	1.0	75
84	Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. American Journal of Cardiology, 1988, 62, 745-750.	0.7	74
85	VEGFR (Vascular Endothelial Growth Factor Receptor) Inhibition Induces Cardiovascular Damage via Redox-Sensitive Processes. Hypertension, 2018, 71, 638-647.	1.3	73
86	Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension.. Hypertension, 1985, 7, I43-8.	1.3	71
87	Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. European Journal of Heart Failure, 2007, 9, 306-309.	2.9	71
88	Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vascular Health and Risk Management, 2009, 5, 577.	1.0	71
89	Left bundle-branch blockâ€"pathophysiology, prognosis, and clinical management. Clinical Cardiology, 2007, 30, 110-115.	0.7	70
90	Pathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative Stress?. International Journal of Molecular Sciences, 2013, 14, 23011-23032.	1.8	70

#	Article	IF	Citations
91	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.3	70
92	Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. European Heart Journal, 2013, 34, 3557-3562.	1.0	69
93	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. European Heart Journal, 2019, 40, 997-1008.	1.0	69
94	Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit.. Circulation Research, 1987, 60, 747-755.	2.0	68
95	Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts.. Circulation, 1993, 87, 192-198.	1.6	68
96	The effects of pregnancy on right ventricular remodeling in women with repaired tetralogy of Fallot. International Journal of Cardiology, 2013, 168, 1847-1852.	0.8	68
97	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. Blood Pressure, 2005, 14, 196-209.	0.7	67
98	Early Impairment of Renal Hemodynamic Reserve in Patients With Asymptomatic Heart Failure Is Restored by Angiotensin II Antagonism. Circulation, 1998, 98, 2849-2854.	1.6	65
99	The PlA1/A2 polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. Journal of Hypertension, 2007, 25, 551-556.	0.3	65
100	Polypharmacy in Heart Failure Patients. Current Heart Failure Reports, 2014, 11, 212-219.	1.3	65
101	Altered Structure, Regulation, and Function of the Gene Encoding the Atrial Natriuretic Peptide in the Stroke-Prone Spontaneously Hypertensive Rat. Circulation Research, 1999, 85, 900-905.	2.0	64
102	Adenoviral RB2/p130 Gene Transfer Inhibits Smooth Muscle Cell Proliferation and Prevents Restenosis After Angioplasty. Circulation Research, 1999, 85, 1032-1039.	2.0	63
103	Left ventricular mass increase is associated with cognitive decline and dementia in the elderly independently of blood pressure. European Heart Journal, 2009, 30, 1525-1529.	1.0	63
104	Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. Journal of Hypertension, 2007, 25, 2158-2167.	0.3	62
105	Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. Journal of Hypertension, 2008, 26, 18-25.	0.3	62
106	The challenge of polypharmacy in cardiovascular medicine. Fundamental and Clinical Pharmacology, 2010, 24, 9-17.	1.0	62
107	Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis, 2013, 230, 191-197.	0.4	62
108	Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. Journal of Human Hypertension, 2017, 31, 258-262.	1.0	62

#	Article	IF	Citations
109	Uncoupling Protein 2: A Key Player and a Potential Therapeutic Target in Vascular Diseases. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	1.9	62
110	The atrial natriuretic peptide: a changing view. Journal of Hypertension, 2001, 19, 1923-1931.	0.3	61
111	NPR-C: a component of the natriuretic peptide family with implications in human diseases. Journal of Molecular Medicine, 2010, 88, 889-897.	1.7	61
112	Hypertension, a Moving Target in COVID-19. Circulation Research, 2021, 128, 1062-1079.	2.0	61
113	An update on hypertensive emergencies and urgencies. Journal of Cardiovascular Medicine, 2015, 16, 372-382.	0.6	60
114	Pharmacological restoration of autophagy reduces hypertension-related stroke occurrence. Autophagy, 2020, 16, 1468-1481.	4.3	60
115	Endothelial Dysfunction and Stroke. Journal of Cardiovascular Pharmacology, 2001, 38, S75-S78.	0.8	59
116	Personalized medicineâ€"a modern approach for the diagnosis and management of hypertension. Clinical Science, 2017, 131, 2671-2685.	1.8	59
117	Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. European Heart Journal, 2001, 22, 1328-1336.	1.0	58
118	Enhanced TNFÎ± and oxidative stress in patients with heart failure: effect of TNFÎ± on platelet O2 - production. Thrombosis and Haemostasis, 2003, 90, 317-325.	1.8	58
119	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 45-52.	1.0	57
120	Differential Modulation of Uncoupling Protein 2 in Kidneys of Stroke-Prone Spontaneously Hypertensive Rats Under High-Salt/Low-Potassium Diet. Hypertension, 2013, 61, 534-541.	1.3	57
121	Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans.. Hypertension, 1993, 21, 1015-1019.	1.3	56
122	Is early and fast blood pressure control important in hypertension management?. International Journal of Cardiology, 2018, 254, 328-332.	0.8	56
123	Pathogenesis of Ischemic Stroke: Role of Epigenetic Mechanisms. Genes, 2020, 11, 89.	1.0	56
124	IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clinical Science, 2011, 120, 377-402.	1.8	55
125	Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. Journal of Molecular Medicine, 2012, 90, 5-13.	1.7	55
126	A role of TNF-alpha gene variant on juvenile ischemic stroke: a case-control study. European Journal of Neurology, 2005, 12, 989-993.	1.7	54

#	Article	IF	Citations
127	Pharmacological Modulation of Autophagy During Cardiac Stress. Journal of Cardiovascular Pharmacology, 2012, 60, 235-241.	0.8	54
128	Evaluation of microvascular structure in humans. Journal of Hypertension, 2014, 32, 2120-2129.	0.3	53
129	Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. Journal of Hypertension, 1999, 17, 1873-1877.	0.3	52
130	Non-pharmacological control of plasma cholesterol levels. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, S1-S16.	1.1	52
131	Why in 2016 are patients with hypertension not 100% controlled? A call to action. Journal of Hypertension, 2016, 34, 1480-1488.	0.3	52
132	Etiology and pathophysiology of stroke as a complex trait. American Journal of Hypertension, 2000, 13, 1139-1148.	1.0	51
133	Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic Î²1-selective receptor blockade. Journal of Hypertension, 2002, 20, 421-428.	0.3	51
134	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. PLoS ONE, 2020, 15, e0237297.	1.1	51
135	NOX4 regulates autophagy during energy deprivation. Autophagy, 2014, 10, 699-701.	4.3	50
136	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart, 2016, 102, 602-609.	1.2	50
137	p66Shc protein, oxidative stress, and cardiovascular complications of diabetes: the missing link. Journal of Molecular Medicine, 2009, 87, 885-891.	1.7	49
138	Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination. Clinical Drug Investigation, 2012, 32, 649-664.	1.1	49
139	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.3	49
140	Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. Journal of Hypertension, 1998, 16, 2039-2043.	0.3	48
141	Beyond hypertension toward guidelines for cardiovascular risk reduction. American Journal of Hypertension, 2004, 17, 1068-1074.	1.0	48
142	Arterial hypertension in cancer: The elephant in the room. International Journal of Cardiology, 2019, 281, 133-139.	0.8	48
143	Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. American Journal of Physiology - Renal Physiology, 1986, 250, F520-F524.	1.3	47
144	Genetic polymorphism of the renin???angiotensin???aldosterone system and arterial hypertension in the Italian population. Journal of Hypertension, 2003, 21, 1853-1860.	0.3	47

#	Article	IF	Citations
145	Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. International Journal of Cardiology, 2005, 102, 327-332.	0.8	47
146	Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000â€“2005 and 2005â€“2011 hypertension surveys. Journal of Human Hypertension, 2015, 29, 696-701.	1.0	47
147	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66Shc. International Journal of Cardiology, 2018, 268, 179-186.	0.8	47
148	Molecular Implications of Natriuretic Peptides in the Protection from Hypertension and Target Organ Damage Development. International Journal of Molecular Sciences, 2019, 20, 798.	1.8	47
149	Insulin blunts sympathetic vasoconstriction through the alpha 2-adrenergic pathway in humans.. Hypertension, 1994, 24, 429-438.	1.3	46
150	Gene polymorphisms of the renin???angiotensin???aldosterone system and the risk of ischemic stroke. Journal of Hypertension, 2004, 22, 2129-2134.	0.3	46
151	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. Journal of Hypertension, 2005, 23, 2113-2118.	0.3	46
152	Studies of the mechanisms underlying impairment of beta-adrenoceptor-mediated effects in human hypertension.. Hypertension, 1983, 5, 584-590.	1.3	45
153	Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. Journal of Human Hypertension, 2005, 19, 331-339.	1.0	45
154	Revisiting the Relationship Between Blood Pressure and Insulin-Like Growth Factor-1. Hypertension, 2014, 63, 1070-1077.	1.3	45
155	Eligibility for the Subcutaneous Implantable Cardioverterâ€Ðefibrillator in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 893-899.	0.8	45
156	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. Journal of Clinical Hypertension, 2016, 18, 551-556.	1.0	45
157	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. European Heart Journal, 2019, 40, 383-391.	1.0	45
158	Intrarenal Determinants of Sodium Retention in Mild Heart Failure. Hypertension, 1997, 30, 168-176.	1.3	45
159	p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor. Biochemical Journal, 2003, 369, 477-484.	1.7	44
160	Efficacy and Safety of a Stepped-Care Regimen Using Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension. Clinical Drug Investigation, 2009, 29, 381-391.	1.1	44
161	Is it time to measure microalbuminuria in hypertension?. Journal of Hypertension, 2003, 21, 1213-1220.	0.3	43
162	Alzheimerâ€™s disease and endothelial dysfunction. Neurological Sciences, 2010, 31, 1-8.	0.9	43

#	Article	IF	Citations
163	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 381-388.	1.0	43
164	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. Journal of the American Heart Association, 2016, 5, .	1.6	43
165	Effect of acebutolol on left ventricular hemodynamics and anatomy in systemic hypertension. American Journal of Cardiology, 1984, 53, 791-796.	0.7	42
166	Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. Journal of the American College of Cardiology, 1987, 10, 787-793.	1.2	41
167	Inhibition of Protein Kinase Cî² Prevents Foam Cell Formation by Reducing Scavenger Receptor A Expression in Human Macrophages. Circulation, 2008, 118, 2174-2182.	1.6	41
168	Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. Journal of Hypertension, 2010, 28, 2342-2350.	0.3	41
169	Heart Failure Progression in Hypertrophic Cardiomyopathyã€€â€“ Possible Insights From Cardiopulmonary Exercise Testing â€“. Circulation Journal, 2016, 80, 2204-2211.	0.7	41
170	Epigenetics and cardiovascular regenerative medicine in the elderly. International Journal of Cardiology, 2018, 250, 207-214.	0.8	41
171	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
172	Can primary care professionalsâ€™ adherence to Evidence Based Medicine tools improve quality of care in Type 2 diabetes mellitus? A systematic review. Diabetes Research and Clinical Practice, 2009, 85, 119-131.	1.1	40
173	Chronic kidney disease in hypertension under specialist care: the I-DEMAND study. Journal of Hypertension, 2010, 28, 156-162.	0.3	40
174	Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease. Journal of the American College of Cardiology, 2012, 59, 1763-1770.	1.2	40
175	Calcium Channel Blockers and Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 121-130.	1.0	40
176	Converting enzyme inhibition prevents the effects of atrial natriuretic factor on baroreflex responses in humans.. Circulation, 1990, 82, 1214-1221.	1.6	39
177	Growth factors in preeclampsia: A vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards?. Cytokine and Growth Factor Reviews, 2013, 24, 411-425.	3.2	39
178	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.4	39
179	Native T1 and T2 provide distinctive signatures in hypertrophic cardiac conditions â€“ Comparison of uremic, hypertensive and hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 306, 102-108.	0.8	39
180	Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. European Heart Journal, 2009, 30, 1364-1371.	1.0	38

#	Article	IF	Citations
181	Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: Insights from the I-DEMAND study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 921-927.	1.1	38
182	QTQS2 ratio as an index of autonomic tone changes. American Journal of Cardiology, 1984, 53, 818-822.	0.7	37
183	Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients.. Circulation, 1988, 77, 997-1002.	1.6	37
184	Blunted sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. A possible compensatory role of atrial natriuretic factor.. Circulation, 1989, 80, 883-892.	1.6	37
185	Angiotensin type 2 receptor in hypertensive cardiovascular disease. Current Opinion in Nephrology and Hypertension, 2011, 20, 125-132.	1.0	37
186	QRS duration and QRS fractionation on surface electrocardiogram are markers of right ventricular dysfunction and atrialization in patients with Ebstein anomaly. European Heart Journal, 2013, 34, 191-200.	1.0	37
187	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 105-108.	1.0	37
188	Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure.. Circulation, 1992, 86, 1800-1809.	1.6	36
189	Hypertension guidelines: criteria that might make them more clinically useful. American Journal of Hypertension, 2002, 15, 917-923.	1.0	36
190	Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. Journal of Applied Physiology, 2007, 103, 1412-1418.	1.2	36
191	Sex differences in hypertension-related renal and cardiovascular diseases in Italy. Journal of Hypertension, 2012, 30, 2378-2386.	0.3	36
192	Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep and Breathing, 2012, 16, 101-110.	0.9	36
193	Mitochondrial Dysfunction Contributes to Hypertensive Target Organ Damage: Lessons from an Animal Model of Human Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	1.9	36
194	Prevalence and clinical outcomes of whiteâ€coat and masked hypertension: Analysis of a large ambulatory blood pressure database. Journal of Clinical Hypertension, 2018, 20, 297-305.	1.0	36
195	Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. International Journal of Molecular Sciences, 2019, 20, 3991.	1.8	36
196	Abnormalities of Endothelial Function in the Pathogenesis of Stroke: The Importance of Endothelin. Journal of Cardiovascular Pharmacology, 2000, 35, S45-S48.	0.8	36
197	Transient enhancement of sympathetic nervous system activity by long-term restriction of sodium intake.. Circulation, 1985, 72, 47-52.	1.6	35
198	Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. Journal of the American Society of Nephrology: JASN, 2006, 17, S36-S43.	3.0	35

#	Article	IF	Citations
199	Restoring the Dysfunctional Endothelium. Current Pharmaceutical Design, 2007, 13, 1053-1068.	0.9	35
200	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. Journal of Hypertension, 2007, 25, 833-839.	0.3	35
201	Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. International Journal of Clinical Practice, 2008, 62, 97-108.	0.8	35
202	Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. Thrombosis and Haemostasis, 2010, 104, 231-242.	1.8	35
203	Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. Heart, 2010, 96, 516-522.	1.2	35
204	Erythropoietin and the heart: facts and perspectives. Clinical Science, 2011, 120, 51-63.	1.8	35
205	Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clinical Chemistry and Laboratory Medicine, 2012, 50, 243-53.	1.4	34
206	C2238 Atrial Natriuretic Peptide Molecular Variant Is Associated With Endothelial Damage and Dysfunction Through Natriuretic Peptide Receptor C Signaling. Circulation Research, 2013, 112, 1355-1364.	2.0	34
207	Cardiovascular health in migrants. Journal of Cardiovascular Medicine, 2014, 15, 683-692.	0.6	34
208	Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. European Heart Journal, 2011, 32, 19-22.	1.0	33
209	Increased temporal dispersion of myocardial repolarization in myotonic dystrophy Type 1. International Journal of Cardiology, 2012, 156, 259-264.	0.8	33
210	Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. International Journal of Cardiology, 2013, 167, 2482-2489.	0.8	33
211	Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. American Journal of Cardiology, 1992, 70, D52-D59.	0.7	32
212	Contribution of Genetic Factors to Renal Lesions in the Stroke-Prone Spontaneously Hypertensive Rat. Hypertension, 2003, 42, 702-706.	1.3	32
213	Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thrombosis and Haemostasis, 2005, 93, 1095-1100.	1.8	32
214	Decreased nocturnal systolic blood pressure fall in older subjects with depression. Aging Clinical and Experimental Research, 2009, 21, 292-297.	1.4	32
215	Role of NADPH oxidase in the regulation of autophagy in cardiomyocytes. Clinical Science, 2015, 128, 387-403.	1.8	32
216	Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. Journal of Hypertension, 2002, 20, 693-699.	0.3	31

#	Article	IF	Citations
217	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. Journal of Hypertension, 2009, 27, S3-S11.	0.3	31
218	Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clinical Science, 2010, 118, 231-240.	1.8	31
219	Prediction of Longâ€Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15â€Year Prospective Followâ€Up Study. Clinical Cardiology, 2010, 33, 700-707.	0.7	31
220	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. Current Hypertension Reports, 2011, 13, 318-324.	1.5	31
221	Osteopontin and Galectinâ€3 Predict the Risk of Ventricular Tachycardia and Fibrillation in Heart Failure Patients with Implantable Defibrillators. Journal of Cardiovascular Electrophysiology, 2014, 25, 609-616.	0.8	31
222	Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. International Journal of Cardiology, 2011, 153, 306-310.	0.8	30
223	Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link?. International Journal of Cardiology, 2013, 167, 2421-2429.	0.8	30
224	Role of oxidative stress in the process of vascular remodeling following coronary revascularization. International Journal of Cardiology, 2018, 268, 27-33.	0.8	30
225	Hypertension, stroke, and endothelium. Current Hypertension Reports, 2005, 7, 68-71.	1.5	29
226	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension, 2009, 27, 941-946.	0.3	29
227	Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. Clinical Science, 2014, 127, 1-13.	1.8	29
228	Protective effects of Brassica oleracea sprouts extract toward renal damage in high-salt-fed SHRSP. Journal of Hypertension, 2015, 33, 1465-1479.	0.3	29
229	Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis, 2016, 246, 214-220.	0.4	29
230	Reduced brain UCP2 expression mediated by microRNA-503 contributes to increased stroke susceptibility in the high-salt fed stroke-prone spontaneously hypertensive rat. Cell Death and Disease, 2017, 8, e2891-e2891.	2.7	29
231	Forearm vascular responsiveness to alpha 1- and alpha 2-adrenoceptor stimulation in patients with congestive heart failure.. Circulation, 1994, 90, 17-22.	1.6	28
232	Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2009, 27, 410-417.	0.3	28
233	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertension Research, 2013, 36, 36-42.	1.5	28
234	Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 248, 326-332.	0.8	28

#	Article	IF	Citations
235	In vitro characterization of mitochondrial function and structure in rat and human cells with a deficiency of the NADH: ubiquinone oxidoreductase Ndufc2 subunit. Human Molecular Genetics, 2017, 26, 4541-4555.	1.4	28
236	Might reninâ€“angiotensin system blockers play a role in the COVID-19 pandemic?. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 248-251.	1.4	28
237	Late phase of nitroglycerin-induced coronary vasodilatation blunted by inhibition of prostaglandin synthesis.. Circulation, 1985, 71, 840-848.	1.6	27
238	Pulsatile Stretch Induces Release of Angiotensin II and Oxidative Stress in Human Endothelial Cells: Effects of ACE Inhibition and AT₁ Receptor Antagonism. Clinical and Experimental Hypertension, 2008, 30, 616-627.	0.5	27
239	Differential modulation of AMPK/PPARÎ±/UCP2 axis in relation to hypertension and aging in the brain, kidneys and heart of two closely related spontaneously hypertensive rat strains. Oncotarget, 2015, 6, 18800-18818.	0.8	27
240	Role of prostaglandins in the renal handling of a salt load in essential hypertension. American Journal of Cardiology, 1985, 55, 116-121.	0.7	26
241	Atrial Natriuretic Peptide and the Baroreflex Control of Circulation. American Journal of Hypertension, 1992, 5, 488-493.	1.0	26
242	Human coronary atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis, 2009, 206, 258-264.	0.4	26
243	Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. Journal of Human Hypertension, 2013, 27, 158-163.	1.0	26
244	Clinical Impact of Nonsustained Ventricular Tachycardia Recorded by the Implantable Cardioverterâ€Ðefibrillator in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2014, 25, 1180-1187.	0.8	26
245	Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway. Frontiers in Pharmacology, 2017, 8, 111.	1.6	26
246	Mitochondrial complex I deficiency and cardiovascular diseases: current evidence and future directions. Journal of Molecular Medicine, 2019, 97, 579-591.	1.7	26
247	Opposite Feedback Control of Renin and Aldosterone Biosynthesis in the Adrenal Cortex by Angiotensin II AT 1 -Subtype Receptors. Hypertension, 1997, 30, 563-568.	1.3	26
248	Role of Tissue Renin in the Regulation of Aldosterone Biosynthesis in the Adrenal Cortex of Nephrectomized Rats. Circulation Research, 1997, 81, 857-864.	2.0	26
249	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 1-14.	1.0	26
250	Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man.. Circulation, 1988, 77, 849-855.	1.6	25
251	Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clinical Therapeutics, 2003, 25, 1469-1489.	1.1	25
252	Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects. Stroke, 2009, 40, 306-308.	1.0	25

#	Article	IF	Citations
253	Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). Journal of Thrombosis and Thrombolysis, 2009, 28, 489-495.	1.0	25
254	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2010, 28, 251-258.	0.3	25
255	Is reactivation of autophagy a possible therapeutic solution for obesity and metabolic syndrome?. Autophagy, 2012, 8, 1252-1254.	4.3	25
256	Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure. Journal of Hypertension, 2013, 31, 1061-1072.	0.3	25
257	Effects of a Long-Term Treatment With Aliskiren or Ramipril on Structural Alterations of Subcutaneous Small-Resistance Arteries of Diabetic Hypertensive Patients. Hypertension, 2014, 64, 717-724.	1.3	25
258	ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 137-47.	1.0	25
259	ARNi: A Novel Approach to Counteract Cardiovascular Diseases. International Journal of Molecular Sciences, 2019, 20, 2092.	1.8	25
260	Valsalva Maneuver in the Assessment of Baroreflex Responsiveness in Borderline Hypertensives. Cardiology, 1983, 70, 6-14.	0.6	24
261	Cardiac autonomic responses to volume overload in normal subjects and in patients with dilated cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1361-H1368.	1.5	24
262	Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians. European Journal of Human Genetics, 2009, 17, 1448-1453.	1.4	24
263	Pulmonary embolism in pregnancy. Journal of Thrombosis and Thrombolysis, 2014, 37, 251-270.	1.0	24
264	Abnormal hormonal and renal responses to saline load in hypertensive patients with parental history of cardiovascular accidents.. Circulation, 1991, 84, 92-100.	1.6	23
265	Beyond hypertension*Toward guidelines for cardiovascular risk reduction*. American Journal of Hypertension, 2004, 17, 1068-1074.	1.0	23
266	Reciprocal congenic lines for a major stroke QTL on rat chromosome 1. Physiological Genomics, 2006, 27, 108-113.	1.0	23
267	Managing cardiovascular risk: the need for change. Journal of Human Hypertension, 2008, 22, 154-157.	1.0	23
268	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. American Journal of Hypertension, 2016, 29, 509-518.	1.0	23
269	Admission heart rate and in-hospital course of patients with Takotsubo syndrome. International Journal of Cardiology, 2018, 273, 15-21.	0.8	23
270	Natriuretic peptides in heart failure: Current achievements and future perspectives. International Journal of Cardiology, 2019, 281, 186-189.	0.8	23

#	Article	IF	Citations
271	Differing hemodynamic responses to atrial natriuretic factor in two models of hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 1986, 250, H871-H878.	1.5	22
272	Effects of Celiprolol on Systemic and Forearm Circulation in Hypertensive Patients: A Doubleâ€Blind Crossâ€Over Study Versus Metoprolol. Journal of Clinical Pharmacology, 1987, 27, 593-600.	1.0	22
273	Angiotensin II-induced atrial natriuretic factor release in dogs is not related to hemodynamic responses.. Circulation Research, 1990, 67, 774-779.	2.0	22
274	Salt-induced plasticity in cardiopulmonary baroreceptor reflexes in salt-resistant hypertensive patients.. Hypertension, 1991, 18, 483-493.	1.3	22
275	Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 409-412.	1.0	22
276	Rac1 Pharmacological Inhibition Rescues Human Endothelial Dysfunction. Journal of the American Heart Association, 2017, 6, .	1.6	22
277	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 1-8.	1.0	22
278	Relation of Left Ventricular Hypertrophy, Afterload, and Contractility to Left Ventricular Performance in Goldblatt Hypertension. American Journal of Hypertension, 1992, 5, 292-301.	1.0	21
279	Î²2-Adrenergic Receptor Gene Polymorphisms and Risk of Ischemic Stroke. American Journal of Hypertension, 2007, 20, 657-662.	1.0	21
280	Evaluation of Systolic Properties in Hypertensive Patients With Different Degrees of Diastolic Dysfunction and Normal Ejection Fraction. American Journal of Hypertension, 2009, 22, 437-443.	1.0	21
281	Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. Journal of Hypertension, 2009, 27, 1804-1813.	0.3	21
282	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Review of Cardiovascular Therapy, 2010, 8, 811-820.	0.6	21
283	Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. Journal of Hypertension, 2018, 36, 1902-1914.	0.3	21
284	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 5-11.	1.0	21
285	Impaired responsiveness of the ventricular sensory receptor in hypertensive patients with left ventricular hypertrophy.. Circulation, 1986, 74, 980-990.	1.6	20
286	Cardiac effects of atrial natriuretic peptide in subjects with normal left ventricular function. American Journal of Cardiology, 1989, 63, 353-357.	0.7	20
287	Differential brain atrial natriuretic peptide expression co-segregates with occurrence of early stroke in the stroke-prone phenotype of the spontaneously hypertensive rat. Journal of Hypertension, 1999, 17, 1849-1852.	0.3	20
288	Differential Regulation of Epstein-Barr Virus (EBV) Latent Gene Expression in Burkitt Lymphoma Cells Infected with a Recombinant EBV Strain. Journal of Virology, 2001, 75, 4929-4935.	1.5	20

#	Article	IF	Citations
289	Ace inhibition and cardiovascular mortality and morbidity in essential hypertension: The end of the search or a need for further investigations?. American Journal of Hypertension, 2002, 15, 367-371.	1.0	20
290	Management of hypertension and stroke prevention: results of the Italian cardiologist survey. International Journal of Clinical Practice, 2009, 63, 207-216.	0.8	20
291	No association between chromosome 12p13 single nucleotide polymorphisms and earlyâ€onset ischemic stroke. Journal of Thrombosis and Haemostasis, 2010, 8, 1858-1860.	1.9	20
292	Relation between right and left ventricular function in patients undergoing chronic dialysis. Journal of Cardiovascular Medicine, 2013, 14, 289-295.	0.6	20
293	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. Cardiovascular Research, 2019, 116, 429-437.	1.8	20
294	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. Scientific Reports, 2020, 10, 13603.	1.6	20
295	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	1.0	20
296	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. Journal of Hypertension, 2021, 39, 376-380.	0.3	20
297	An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation. Cell Death and Disease, 2021, 12, 919.	2.7	20
298	Beta blockers and left ventricular hypertrophy in hypertension. American Heart Journal, 1987, 114, 975-983.	1.2	19
299	Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. Journal of Human Hypertension, 2007, 21, 822-824.	1.0	19
300	Hypertension Control and Cardiometabolic Risk: A Regional Perspective. Cardiology Research and Practice, 2012, 2012, 1-10.	0.5	19
301	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	1.0	19
302	A guide for easy- and difficult-to-treat hypertension. International Journal of Cardiology, 2014, 172, 17-22.	0.8	19
303	Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 241-246.	1.0	19
304	A Next-Generation Sequencing Approach to Identify Gene Mutations in Early- and Late-Onset Hypertrophic Cardiomyopathy Patients of an Italian Cohort. International Journal of Molecular Sciences, 2016, 17, 1239.	1.8	19
305	Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study. European Journal of Preventive Cardiology, 2016, 23, 1690-1699.	0.8	19
306	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. Nature Reviews Cardiology, 2017, 14, 560-565.	6.1	19

#	Article	IF	Citations
307	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. Journal of Clinical Hypertension, 2018, 20, 1238-1246.	1.0	19
308	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 271, 125-131.	0.8	19
309	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. International Journal of Cardiology, 2019, 286, 127-133.	0.8	19
310	Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension. Hypertension, 2020, 76, 1753-1761.	1.3	19
311	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	0.8	19
312	Use of aliskiren in a â€˜real-lifeâ€™ model of hypertension management. Journal of Hypertension, 2012, 30, 194-203.	0.3	19
313	The Autonomic Nervous Tone Abnormalities in the Genesis of the Impaired Baroreflex Responsiveness in Borderline Hypertensive Subjects. Clinical Science, 1982, 62, 581-588.	1.8	18
314	Dietary salt excess unmasks blunted aldosterone suppression and sodium retention in the stroke-prone phenotype of the spontaneously hypertensive rat. Journal of Hypertension, 1993, 11, 793-798.	0.3	18
315	Renal implications of the reninâ€“angiotensinâ€“aldosterone system blockade in heart failure. Journal of Hypertension, 2000, 18, 1545-1551.	0.3	18
316	Characterization of caveolae from rat heart: Localization of postreceptor signal transduction molecules and their rearrangement after norepinephrine stimulation. , 2000, 77, 529-539.		18
317	Direct Renin Inhibition. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 93-105.	1.0	18
318	The Changing Role of Hypertension Societies. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 1-2.	1.0	18
319	Renin as a biomarker of cardiovascular disease in clinical practice. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 312-317.	1.1	18
320	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vascular Health and Risk Management, 2012, 8, 371.	1.0	18
321	Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study. Internal and Emergency Medicine, 2014, 9, 293-302.	1.0	18
322	Reducing Cardiovascular and Cancer Risk: How to Address Global Primary Prevention in Clinical Practice. Clinical Cardiology, 2015, 38, 387-394.	0.7	18
323	Novel antidiabetic drugs and cardiovascular risk: Primum non nocere. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 759-766.	1.1	18
324	Tortuosity, Recurrent Segments, and Bridging of the Epicardial Coronary Arteries in Patients With the Takotsubo Syndrome. American Journal of Cardiology, 2017, 119, 243-248.	0.7	18

#	Article	IF	Citations
325	Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2017, 28, 103-108.	0.8	18
326	Executive Summary of the 2018 Joint Consensus Document onÂCardiovascular Disease Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 327-341.	1.0	18
327	Radionuclide Monitoring of Cardiac Adaptations to Volume Loading in Patients With Dilated Cardiomyopathy and Mild Heart Failure. Circulation, 1995, 92, 2511-2518.	1.6	18
328	Prolonged duration of myocardial ischemia in patients with coronary heart disease and impaired cardiopulmonary baroreceptor sensitivity.. Circulation, 1990, 81, 1792-1802.	1.6	17
329	Physicians, patients, and public knowledge and perception regarding hypertension and stroke: a review of survey studies. Current Medical Research and Opinion, 2006, 22, 1319-1330.	0.9	17
330	Association of physiciansâ€™ accuracy in recording with quality of care in cardiovascular medicine. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 722-728.	3.1	17
331	Increased cardiac output and lowered peripheral resistance during metoprolol treatment. Acta Medica Scandinavica, 1983, 213, 105-110.	0.0	17
332	Hypertension as an Underlying Factor in Heart Failure With Preserved Ejection Fraction. Journal of Clinical Hypertension, 2010, 12, 277-283.	1.0	17
333	Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients. Journal of Hypertension, 2012, 30, 1468-1477.	0.3	17
334	Erythropoietin in cardiac disease. Journal of Cardiovascular Medicine, 2013, 14, 870-878.	0.6	17
335	Atrial Natriuretic Peptide Single Nucleotide Polymorphisms in Patients with Nonfamilial Structural Atrial Fibrillation. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S12239.	0.6	17
336	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 387-393.	1.0	17
337	Ferrari Corporate Wellness Program: Results of a Pilot Analysis and the â€œDragâ€•Impact in the Workplace. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 261-266.	1.0	17
338	Ambulatory blood pressure and arterial stiffness webâ€based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	17
339	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 91-102.	1.0	17
340	Hemodynamic responses to atrial natriuretic factor in nephrectomized rabbits: attenuation of the circulatory consequences of acute volume expansion.. Circulation Research, 1988, 63, 322-329.	2.0	16
341	The REassessment of Antihypertensive Chronic Therapy (REACT) Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 175-185.	1.0	16
342	Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. Clinical Research in Cardiology, 2012, 101, 761-766.	1.5	16

#	Article	IF	Citations
343	NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. International Journal of Cardiology, 2012, 155, 311-312.	0.8	16
344	Pâ€Wave Duration in Lead aVR and the Risk of Atrial Fibrillation in Hypertension. Annals of Noninvasive Electrocardiology, 2015, 20, 167-174.	0.5	16
345	Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. Advances in Therapy, 2019, 36, 278-297.	1.3	16
346	Prognostic relevance of GRACE risk score in Takotsubo syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 721-728.	0.4	16
347	Italian Society of Arterial Hypertension (SIIA) Position Paper on the Role of Renal Denervation in the Management of the Difficult-to-Treat Hypertensive Patient. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 109-117.	1.0	16
348	Effects of atrial natriuretic factor on human platelet function. Life Sciences, 1985, 37, 1395-1402.	2.0	15
349	Contribution of the Renin-Angiotensin System and of the Sympathetic Nervous System to Blood Pressure Homeostasis During Chronic Restriction of Sodium Intake. American Journal of Hypertension, 1988, 1, 353-358.	1.0	15
350	Stable Improvement in Large Artery Compliance after Long-term Antihypertensive Treatment with Enalapril. American Journal of Hypertension, 1988, 1, 181-183.	1.0	15
351	Modulatory Role of Angiotensin-II in the Secretion of Atrial Natriuretic Factor in Rabbits. Endocrinology, 1991, 128, 2427-2431.	1.4	15
352	Effects of losartan treatment on cardiac autonomic control during volume loading in patients with DCM. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H86-H92.	1.5	15
353	Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists. Journal of Human Hypertension, 2005, 19, 93-102.	1.0	15
354	Unexpectedly low mutation rates in betaâ€myosin heavy chain and cardiac myosin binding protein genes in italian patients with hypertrophic cardiomyopathy. Journal of Cellular Physiology, 2011, 226, 2894-2900.	2.0	15
355	Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 11-27.	0.2	15
356	Inhibition of the reninâ€“angiotensinâ€“aldosterone system. Journal of Hypertension, 2012, 30, 647-654.	0.3	15
357	Simultaneous Takotsubo syndrome in two sisters. International Journal of Cardiology, 2013, 165, e49-e50.	0.8	15
358	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. International Journal of Cardiology, 2017, 248, 342-348.	0.8	15
359	Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1924-1931.	0.7	15
360	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 51-59.	1.0	15

#	Article	IF	Citations
361	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. Journal of Clinical Medicine, 2020, 9, 1636.	1.0	15
362	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. International Journal of Cardiology, 2020, 316, 172-179.	0.8	15
363	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. Journal of Cardiovascular Medicine, 2021, 22, 832-839.	0.6	15
364	Trehalose, a natural disaccharide, reduces stroke occurrence in the stroke-prone spontaneously hypertensive rat. Pharmacological Research, 2021, 173, 105875.	3.1	15
365	Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes. Oncotarget, 2018, 9, 35028-35040.	0.8	15
366	Metabolic syndrome and chronic kidney disease in high-risk Italian hypertensive patients: the I-DEMAND study. Journal of Nephrology, 2012, 25, 63-74.	0.9	15
367	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	1.1	15
368	Treatment priorities and current prescribing patterns in hypertension: results of GRASP, an international physician survey. Current Medical Research and Opinion, 2004, 20, 1151-1160.	0.9	14
369	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	0.6	14
370	Managing hypertension in cardiology practice according to risk profile. International Journal of Clinical Practice, 2008, 62, 1403-1412.	0.8	14
371	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. American Journal of Hypertension, 2011, 24, 1060-1068.	1.0	14
372	Non-Invasive Diagnostic Testing for Coronary Artery Disease in the Hypertensive Patient: Potential Advantages of a Risk Estimation-Based Algorithm. American Journal of Hypertension, 2012, 25, 1226-35.	1.0	14
373	Global cardiovascular risk management in different Italian regions: An analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 635-642.	1.1	14
374	Novel Î±-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease. Gene, 2014, 535, 365-369.	1.0	14
375	Cardiovascular disease in women with HIV-1 infection. International Journal of Cardiology, 2017, 241, 50-56.	0.8	14
376	A differential expression of uncoupling protein-2 associates with renal damage in stroke-resistant spontaneously hypertensive rat/stroke-prone spontaneously hypertensive rat-derived stroke congenic lines. Journal of Hypertension, 2017, 35, 1857-1871.	0.3	14
377	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 463-472.	1.0	14
378	Fifteen years of <scp>LIFE</scp> (Losartan Intervention for Endpoint Reduction in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (Hyperte Hypertension, 2018, 20, 1153-1159.	1.0	14

#	Article	IF	Citations
379	Implications of Guidelines for Hypertension Management in Europe. Circulation Research, 2019, 124, 972-974.	2.0	14
380	Reclassification of Hypertensive Outpatients According to New US Guidelines on High Blood Pressure. American Journal of Hypertension, 2019, 32, 77-87.	1.0	14
381	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 373-377.	1.0	14
382	Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy. European Journal of Internal Medicine, 2020, 78, 95-100.	1.0	14
383	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. Frontiers in Physiology, 2021, 12, 652163.	1.3	14
384	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	1.0	14
385	Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2008, 6, 258-271.	0.4	14
386	Impaired control of vasopressin release in hypertensive subjects with cardiac hypertrophy.. Hypertension, 1987, 10, 595-602.	1.3	13
387	In the search for stroke genes: a long and winding road. American Journal of Hypertension, 2004, 17, 197-202.	1.0	13
388	Pregnancy-Associated Plasma Protein-A and Acute Coronary Syndromes: Cause or Consequence?. Journal of the American College of Cardiology, 2005, 46, 1583-1584.	1.2	13
389	A protective role of a cholesteryl ester transfer protein gene variant towards ischaemic stroke in Sardinians. Journal of Internal Medicine, 2007, 262, 555-561.	2.7	13
390	Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Review of Cardiovascular Therapy, 2009, 7, 115-123.	0.6	13
391	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	1.0	13
392	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 37-47.	1.0	13
393	New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. Integrated Blood Pressure Control, 2012, 5, 19.	0.4	13
394	Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. European Journal of Internal Medicine, 2013, 24, 80-82.	1.0	13
395	A Novel Electrocardiographic Tâ€Wave Measurement (Tpâ€Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for Firstâ€Line Electrocardiographic Evaluation. Journal of Clinical Hypertension, 2015, 17, 441-449.	1.0	13
396	C2238/Î±ANP modulates apolipoprotein E through Egr-1/miR199a in vascular smooth muscle cells in vitro. Cell Death and Disease, 2015, 6, e2033-e2033.	2.7	13

#	Article	IF	Citations
397	Novel Insights Into the Mechanisms Regulating Pro-Atrial Natriuretic Peptide Cleavage in the Heart and Blood Pressure Regulation. Circulation Research, 2016, 118, 196-198.	2.0	13
398	Favourable impact of statin use on diastolic blood pressure levels. Journal of Hypertension, 2017, 35, 2086-2094.	0.3	13
399	Dickkopf-3 Causes Neuroprotection by Inducing Vascular Endothelial Growth Factor. Frontiers in Cellular Neuroscience, 2018, 12, 292.	1.8	13
400	New approach to blood pressure control: Triple combination pill. Trends in Cardiovascular Medicine, 2020, 30, 72-77.	2.3	13
401	Effect of furosemide on plasma concentration and Î²-blockade by propranolol. Clinical Pharmacology and Therapeutics, 1979, 26, 433-436.	2.3	12
402	Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. American Journal of Cardiology, 1994, 74, A36-A42.	0.7	12
403	Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. Journal of Hypertension, 1998, 16, 151-156.	0.3	12
404	Analysis of the genetic basis of the endothelium-dependent impaired vasorelaxation in the stroke-prone spontaneously hypertensive rat. Journal of Hypertension, 2000, 18, 161-165.	0.3	12
405	Effect of a regulatory mutation on the rat atrial natriuretic peptide gene transcription. Peptides, 2002, 23, 555-560.	1.2	12
406	Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. Journal of Hypertension, 2007, 25, 2390-2397.	0.3	12
407	Depression is associated with increased occurrence of left ventricle concentric geometry in older subjects independently of blood pressure levels. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 915-921.	1.1	12
408	The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes. Clinical Science, 2013, 125, 183-189.	1.8	12
409	Clinical Management of Patients with Hypertension and High Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 107-117.	1.0	12
410	Electrocardiographic evolution in patients with hypertrophic cardiomyopathy who develop a left ventricular apical aneurysm. Journal of Electrocardiology, 2015, 48, 818-825.	0.4	12
411	Long-Term Outcome of Acute Coronary Syndromes in Young Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 77-84.	1.0	12
412	Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 850-857.	1.1	12
413	Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. Cardiovascular Therapeutics, 2018, 36, e12471.	1.1	12
414	The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. International Journal of Molecular Sciences, 2018, 19, 540.	1.8	12

#	Article	IF	Citations
415	Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 399-404.	1.0	12
416	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Hypertension, 2019, 74, 130-136.	1.3	12
417	Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?. International Journal of Cardiology, 2020, 321, 150-154.	0.8	12
418	Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy. Cardiovascular Diagnosis and Therapy, 2015, 5, 271-9.	0.7	12
419	Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. Aging Clinical and Experimental Research, 2005, 17, 46-53.	1.4	12
420	Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. Vascular Health and Risk Management, 0, Volume 18, 507-515.	1.0	12
421	Baroreflex responsiveness in borderline hypertensives: a study with neostigmine. Cardiovascular Research, 1981, 15, 436-442.	1.8	11
422	Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy. Journal of Hypertension, 2010, 28, 1638-1645.	0.3	11
423	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. International Journal of Cardiology, 2011, 149, 250-252.	0.8	11
424	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. Clinical Cardiology, 2011, 34, 560-566.	0.7	11
425	Olmesartan-based therapies. Journal of Hypertension, 2013, 31, S13-S17.	0.3	11
426	QT spatial dispersion and sudden cardiac death in hypertrophic cardiomyopathy: Time for reappraisal. Journal of Cardiology, 2017, 70, 310-315.	0.8	11
427	A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-13.	1.9	11
428	Conventional and new electrocardiographic criteria for hypertensionâ€mediated cardiac organ damage: A narrative review. Journal of Clinical Hypertension, 2019, 21, 1863-1871.	1.0	11
429	Molecular and clinical implications of natriuretic peptides in aortic valve stenosis. Journal of Molecular and Cellular Cardiology, 2019, 129, 266-271.	0.9	11
430	The neglected issue of cardiac amyloidosis in trials on heart failure with preserved ejection fraction in the elderly. European Journal of Heart Failure, 2020, 22, 1740-1741.	2.9	11
431	Regulation of Aldosterone Biosynthesis by Adrenal Renin Is Mediated Through AT ₁ Receptors in Renin Transgenic Rats. Circulation Research, 1995, 77, 73-79.	2.0	11
432	Understanding and treating hypertension in diabetic populations. Cardiovascular Diagnosis and Therapy, 2015, 5, 353-63.	0.7	11

#	Article	IF	Citations
433	Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. International Journal of Cardiology, 2022, 349, 134-137.	0.8	11
434	Influence of digitalis on left ventricular functional response to exercise in congestive heart failure. American Journal of Cardiology, 1996, 77, 480-485.	0.7	10
435	Arterial Hypertension and Cardiac Damage. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 141-170.	1.0	10
436	Bridging science and health policy in cardiovascular disease: focus on lipid management. Atherosclerosis Supplements, 2009, 10, 3-21.	1.2	10
437	Physical activity is inversely associated with microalbuminuria in hypertensive patients at high cardiovascular risk: data from I-SEARCH. European Journal of Preventive Cardiology, 2012, 19, 1066-1073.	0.8	10
438	Antihypertensive Efficacy and Safety of Olmesartan Medoxomil and Ramipril in Elderly Mild to Moderate Essential Hypertensive Patients With or Without Metabolic Syndrome. Drugs and Aging, 2012, 29, 981-992.	1.3	10
439	Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs and Aging, 2013, 30, 987-998.	1.3	10
440	Common genetic variants in selected Ca2+ signaling genes and the risk of appropriate ICD interventions in patients with heart failure. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 169-177.	0.6	10
441	The C2238Î±ANP Variant Is a Negative Modulator of Both Viability and Function of Coronary Artery Smooth Muscle Cells. PLoS ONE, 2014, 9, e113108.	1.1	10
442	Does clinical governance influence the appropriateness of hospital stay?. BMC Health Services Research, 2015, 15, 142.	0.9	10
443	Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment. Journal of Hypertension, 2016, 34, 567-587.	0.3	10
444	Natriuretic peptides and volume handling in heart failure: the paradigm of a new treatment. European Journal of Heart Failure, 2016, 18, 442-444.	2.9	10
445	NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovascular Revascularization Medicine, 2016, 17, 162-168.	0.3	10
446	Safety and efficacy of antiâ€tachycardia pacing in patients with hypertrophic cardiomyopathy implanted with an ICD. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 610-616.	0.5	10
447	Hypertension in the elderly: which are the blood pressure threshold values?. European Heart Journal Supplements, 2019, 21, B105-B106.	0.0	10
448	Clinical characteristics of patients with takotsubo syndrome recurrence: An observational study with long-term follow-up. International Journal of Cardiology, 2021, 329, 23-27.	0.8	10
449	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 633878.	1.1	10
450	Effects of high-cholesterol and atherogenic diets on vascular relaxation in spontaneously hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H647-H654.	1.5	9

#	Article	IF	Citations
451	Antihypertensive therapy and cerebrovascular protection. Current Opinion in Nephrology and Hypertension, 2006, 15, 498-504.	1.0	9
452	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 73-102.	1.0	9
453	The cardiovascular continuum refined: A hypothesis. Blood Pressure, 2010, 19, 273-277.	0.7	9
454	End-Organ Protection in Patients with Hypertension. Drugs, 2011, 71, 1003-1017.	4.9	9
455	Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort. International Journal of Cardiology, 2011, 152, 245-246.	0.8	9
456	Angiotensin receptor modulation and cardiovascular remodeling. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 381-384.	1.0	9
457	Antihypertensive Efficacy of Olmesartan Medoxomil and Ramipril in Elderly Patients with Mild to Moderate Hypertension Grouped According to Renal Function Status. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 213-222.	1.0	9
458	Pathophysiology of biventricular dysfunction during hemodialysis: Emerging concepts. International Journal of Cardiology, 2012, 155, 478-479.	0.8	9
459	Plasma Renin and Cardiovascular Risk: What Is the Evidence for an Association?. Cardiology, 2013, 125, 50-59.	0.6	9
460	Open-Label Study Assessing the Long-term Efficacy and Safety of Triple Olmesartan/Amlodipine/Hydrochlorothiazide Combination Therapy for Hypertension. Advances in Therapy, 2014, 31, 561-574.	1.3	9
461	Olmesartan vs. Ramipril in Elderly Hypertensive Patients: Review of Data from Two Published Randomized, Double-Blind Studies. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 1-19.	1.0	9
462	T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. Journal of Cardiovascular Medicine, 2016, 17, 601-607.	0.6	9
463	Transfemoral approach with systematic use of FemoSealâ„¢ closure device compared to transradial approach in primary angioplasty. Catheterization and Cardiovascular Interventions, 2016, 87, 849-854.	0.7	9
464	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 313-329.	1.0	9
465	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. Clinical Cardiology, 2018, 41, 788-796.	0.7	9
466	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. Current Hypertension Reports, 2019, 21, 85.	1.5	9
467	A systematic review on focal takotsubo syndrome: a not-so-small matter. Heart Failure Reviews, 2022, 27, 271-280.	1.7	9
468	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	0.8	9

#	Article	IF	Citations
469	Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?. European Heart Journal, 2021, 42, 3753-3755.	1.0	9
470	Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach. Hypertension, 2021, 78, 1868-1870.	1.3	9
471	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	1.0	9
472	Histamine and hypoxic pulmonary hypertension A quantitative study. Cardiovascular Research, 1978, 12, 752-757.	1.8	8
473	Reflex control of coronary vascular tone by cardiopulmonary receptors in humans. Journal of the American College of Cardiology, 1988, 11, 944-952.	1.2	8
474	Transition from asymptomatic left ventricular dysfunction to congestive heart failure. Journal of Cardiac Failure, 1995, 1, 409-419.	0.7	8
475	Hypertension and Heart Failure: Role of Neurohormonal Mechanisms. Clinical and Experimental Hypertension, 2004, 26, 603-610.	0.5	8
476	Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH. Clinical Research in Cardiology, 2010, 99, 825-832.	1.5	8
477	Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert Review of Cardiovascular Therapy, 2012, 10, 1061-1072.	0.6	8
478	Cardiac Magnetic Resonance Evaluation of the Impact of Interventricular and Intraventricular Dyssynchrony on Cardiac Ventricular Systolic and Diastolic Function in Patients With Isolated Left Bundle Branch Block. American Journal of Cardiology, 2012, 110, 1651-1656.	0.7	8
479	Triple combination therapy to improve blood pressure control: experience with olmesartanâ€“amlodipineâ€“hydrochlorothiazide therapy. Expert Opinion on Pharmacotherapy, 2012, 13, 2687-2697.	0.9	8
480	Clinical Management of Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 251-256.	1.0	8
481	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Scientific Reports, 2017, 7, 3797.	1.6	8
482	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 331-339.	1.0	8
483	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 253-259.	1.0	8
484	Blood Pressure Target Achievement Under Monotheraphy: A Real-Life Appraisal. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 587-596.	1.0	8
485	A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Frontiers in Physiology, 2021, 12, 643721.	1.3	8
486	Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome. Frontiers in Cardiovascular Medicine, 2021, 8, 703418.	1.1	8

#	Article	IF	Citations
487	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. Journal of Hypertension, 2020, 38, 1005-1015.	0.3	8
488	Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?. European Cardiology Review, 2020, 15, e21.	0.7	8
489	Effects of oral salt loading on beta-adrenergic receptor responsiveness in normal and hypertensive subjects. Cardiovascular Research, 1982, 16, 732-737.	1.8	7
490	Renal Function in Borderline Hypertensive First-Degree Relatives of Essential Hypertensives. Cardiology, 1982, 69, 288-296.	0.6	7
491	Effects of Chronic Antihypertensive Treatment with Ketanserin Versus Metoprolol on Blood Pressure and Large Arteries' Compliance in Humans: A Crossâ€Over Doubleâ€Blind Study. Journal of Clinical Pharmacology, 1988, 28, 332-338.	1.0	7
492	Midwall LV mechanics in rats with or without renovascular hypertension: effect of different Na+ intakes. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 270, H628-H637.	1.5	7
493	Angiotensin II-receptor antagonist in the treatment of hypertension. Current Hypertension Reports, 2005, 7, 287-293.	1.5	7
494	The management of the type 2 diabetic patient with hypertension â€“ too late and too little: Suggested improvements. Blood Pressure, 2008, 17, 250-259.	0.7	7
495	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 19-30.	1.0	7
496	Modern Clinical Management of Arterial Hypertension. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 3-11.	1.0	7
497	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. International Journal of Cardiology, 2012, 158, 158-160.	0.8	7
498	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. ISRN Cardiology, 2014, 2014, 1-7.	1.6	7
499	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 29-36.	1.0	7
500	Impact of Hypertension on Global Cardiovascular Risk Stratification: Analysis of a Large Cohort of Outpatient Population in Italy. Clinical Cardiology, 2015, 38, 39-47.	0.7	7
501	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. Internal and Emergency Medicine, 2015, 10, 943-954.	1.0	7
502	Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. Data in Brief, 2016, 7, 1409-1412.	0.5	7
503	T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients. Journal of Cardiovascular Translational Research, 2018, 11, 36-41.	1.1	7
504	Hypertensive crisis management in the emergency room. Journal of Hypertension, 2020, 38, 33-34.	0.3	7

#	Article	IF	Citations
505	Natriuretic Peptides, Cognitive Impairment and Dementia: An Intriguing Pathogenic Link with Implications in Hypertension. Journal of Clinical Medicine, 2020, 9, 2265.	1.0	7
506	Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. Journal of Clinical Medicine, 2020, 9, 1348.	1.0	7
507	Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high-output heart failure due to high-flow forearm arteriovenous fistula. Journal of Vascular Access, 2020, 21, 753-759.	0.5	7
508	Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. Journal of Human Hypertension, 2021, , .	1.0	7
509	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. European Heart Journal, 2021, 42, 2814-2815.	1.0	7
510	Prevalence of microalbuminuria in hypertensive patients and its associated cardiovascular risk in clinical cardiology: Moroccan results of the global i-SEARCH survey - a sub-analysis of a survey with 21,050 patients in 26 countries worldwide. Cardiovascular Journal of Africa, 2010, 21, 200-5.	0.2	7
511	Ouabain-induced reflex coronary vasodilatation mediated by cardiac receptors. American Journal of Physiology - Heart and Circulatory Physiology, 1984, 246, H664-H670.	1.5	6
512	Relationships between Left Ventricular Mass and Clinical, Biohumoral and Hemodynamic Parameters in Human Hypertension. Cardiology, 1984, 71, 1-12.	0.6	6
513	Carotid sinus reflex control of coronary blood flow in human subjects. Journal of the American College of Cardiology, 1985, 5, 1312-1318.	1.2	6
514	Effects of atrial natriuretic peptide on glomerular filtration rate in essential hypertension: a radionuclide study. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 32-7.	2.2	6
515	Defective suppression of the aldosterone biosynthesis during stroke permissive diet in the stroke-prone phenotype of the spontaneously hypertensive rat. Basic Research in Cardiology, 2000, 95, 84-92.	2.5	6
516	Non-random chromosomal distribution of SSLPs: systematic assessment using a novel genetic linkage map between two closely related rat strains. Cytogenetic and Genome Research, 2001, 95, 64-72.	0.6	6
517	Cardiovascular Risk Profile in 14???513 Patients with Essential Hypertension Followed by Italian Specialist Physicians. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 165-173.	1.0	6
518	Nitric Oxide Release Is Impaired in Hypertensive Individuals With Familial History of Stroke. American Journal of Hypertension, 2006, 19, 1213-1216.	1.0	6
519	Arterial Stiffness and Cognitive Impairment in the Elderly. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 33-37.	1.0	6
520	Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrology Dialysis Transplantation, 2010, 25, 3465-3471.	0.4	6
521	Chronic Kidney Disease in the Hypertensive Patient. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 31-36.	1.0	6
522	2010 Position Paper of the Italian Society of Hypertension (SIIA). High Blood Pressure and Cardiovascular Prevention, 2011, 18, 37-40.	1.0	6

#	Article	IF	Citations
523	An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 73-83.	1.0	6
524	NT-proAtrial Natriuretic Peptide as a possible biomarker of cardiopulmonary involvement in sarcoidosis. European Journal of Internal Medicine, 2013, 24, 278-284.	1.0	6
525	Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. Journal of Human Hypertension, 2015, 29, 409-416.	1.0	6
526	Integrated Preclinical Cardiovascular Prevention: A New Paradigm to Face Growing Challenges of Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2015, 15, 163-170.	1.0	6
527	Hypertension Across the Atlantic: A Sprint or a Marathon?. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 99-102.	1.0	6
528	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24â€hour ambulatory blood pressure database. Journal of Clinical Hypertension, 2018, 20, 967-975.	1.0	6
529	Natural History of Treated and Untreated Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 33-44.	0.1	6
530	Tales in Cardiology. European Heart Journal, 2019, 40, 800-802.	1.0	6
531	Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. Journal of Cardiovascular Medicine, 2019, 20, 771-779.	0.6	6
532	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. Journal of Human Hypertension, 2019, 33, 298-307.	1.0	6
533	COVID-19 and the Forgotten Majority. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 339-339.	1.0	6
534	The EMPEROR-Preserved study: end of the search for the â€œPhoenixâ€•or beginning of a new season for trials in heart failure with preserved ejection fraction. European Heart Journal, 2021, 42, 4621-4623.	1.0	6
535	Role of a molecular variant of rat atrial natriuretic Peptide gene in vascular remodeling. Annals of Clinical and Laboratory Science, 2007, 37, 135-40.	0.2	6
536	SARS-CoV-2 infection markedly increases long-term cardiovascular risk. European Heart Journal, 2022, 43, 1899-1900.	1.0	6
537	Influence of O2 deprivation, reduced flow, and temperature on release of ANP from rabbit hearts. American Journal of Physiology - Heart and Circulatory Physiology, 1995, 268, H2352-H2357.	1.5	5
538	Genetic Susceptibility to Cerebrovascular Accidents. Journal of Cardiovascular Pharmacology, 2001, 38, S71-S74.	0.8	5
539	Altered regulation of endothelin A receptor subtype in the cerebral arterioles in response to a Japanese-style diet, in stroke-prone hypertensive rats. Journal of Hypertension, 2003, 21, 105-113.	0.3	5
540	Hypertension therapy: Mixing, matching, and meeting targets. Advances in Therapy, 2004, 21, 107-122.	1.3	5

#	Article	IF	Citations
541	Angiotensin II: An amplifier of cardiovascular risk. Current Hypertension Reports, 2004, 6, 247-248.	1.5	5
542	Extracellular Matrix Remodelling in Myocardial Hypertrophy and Failure. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 195-199.	1.0	5
543	Preclinical effects of healthy obesity on inappropriate left ventricular mass and systolic function. International Journal of Cardiology, 2013, 167, 3047-3049.	0.8	5
544	Clinical Management of Coronary Heart Disease in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 129-134.	1.0	5
545	Î± _{2A} -Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19*2 Genetic Variant. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1314-1319.	1.1	5
546	Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines. Clinical Interventions in Aging, 2015, 10, 1575.	1.3	5
547	Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention. Current Hypertension Reports, 2015, 17, 553.	1.5	5
548	Shooting vascular oxidative stress: new hopes for stroke patients?: FigureÂ1. European Heart Journal, 2015, 36, 1573-1575.	1.0	5
549	New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 333-335.	1.0	5
550	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2016, 18, 127.	1.3	5
551	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 243-253.	1.0	5
552	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clinical Hypertension, 2017, 23, 10.	0.7	5
553	Inflammatory residual risk: An emerging target to reduce cardiovascular disease?. Clinical Cardiology, 2018, 41, 437-439.	0.7	5
554	Antihypertensive drugs and the risks of cancer: More fakes than facts. European Journal of Preventive Cardiology, 2021, 28, 1323-1326.	0.8	5
555	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Cardiovascular Research, 2021, 117, 1992-1994.	1.8	5
556	Prognostic implications of nonsustained ventricular tachycardia morphology in highâ€risk patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 2093-2098.	0.8	5
557	Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: a retrospective study of an Italian cohort. Expert Review of Clinical Immunology, 2021, 17, 661-666.	1.3	5
558	Recommendations for the clinical use of cardiac natriuretic peptides. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2005, 6, 430-46.	0.1	5

#	Article	IF	Citations
559	Indenolol: A New Antihypertensive Agent: Efficacy, Toxicity, and Hemodynamic Effects in a Crossover Doubleâ€Blind Study With Metoprolol. Journal of Clinical Pharmacology, 1985, 25, 328-336.	1.0	4
560	Digitalis restores the forearm sympathetic response to cardiopulmonary receptor unloading in hypertensive patients with left ventricular hypertrophy. Journal of Hypertension, 1993, 11, 1395-1402.	0.3	4
561	Identification of adrenomedullin as a candidate gene in the stroke-prone phenotype of spontaneously hypertensive rats (SHRSP). American Journal of Hypertension, 1998, 11, 5A.	1.0	4
562	The case for blood pressure control in risk groups. International Journal of Clinical Practice, 2004, 58, 844-849.	0.8	4
563	Role of Genetic Factors in the Etiopathogenesis of Cerebrovascular Accidents: From an Animal Model to the Human Disease. Cellular and Molecular Neurobiology, 2004, 24, 581-588.	1.7	4
564	Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents'. European Heart Journal, 2005, 27, 1506-1507.	1.0	4
565	Cardiovascular Risk Management in Clinical Practice. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 9-16.	1.0	4
566	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 47-51.	1.0	4
567	2008 White Paper for Implementing Strategies and Interventions for Cardiovascular Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 63-73.	1.0	4
568	Overview of the i-SEARCH Global Study. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 217-224.	1.0	4
569	Cardiovascular Risk in Hypertension â€“ Can We Ask for More?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 255-268.	1.0	4
570	NT-proANP/ANP is a Determinant of Vascular Damage in Humans. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 117-120.	1.0	4
571	Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy. Expert Review of Cardiovascular Therapy, 2011, 9, 829-840.	0.6	4
572	Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. Current Signal Transduction Therapy, 2012, 7, 265-288.	0.3	4
573	RyR2 Common Gene Variant G1886S and the Risk of Ventricular Arrhythmias in ICD Patients with Heart Failure. Journal of Cardiovascular Electrophysiology, 2015, 26, 656-661.	0.8	4
574	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). High Blood Pressure and Cardiovascular Prevention, 2015, 22, 135-142.	1.0	4
575	Clinical management of patients with hypertension and high cardiovascular risk in specialised centers and in general practice. Analysis from an Italian Survey Questionnaire. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 866-874.	1.1	4
576	Outcomes of early invasive treatment strategy in elderly patients with non-ST elevation acute coronary syndromes. Journal of Cardiovascular Medicine, 2016, 17, 736-743.	0.6	4

#	Article	IF	Citations
577	BNP level and post-transcatheter aortic valve replacement outcome: an intriguing J-shaped relationship. European Heart Journal, 2020, 41, 970-972.	1.0	4
578	Atrial fibrillation and ischaemic heart disease: should we use acetylsalicylic acid beside anticoagulants?. European Heart Journal Supplements, 2020, 22, L166-L169.	0.0	4
579	Sacubitril/Valsartan: Potential Impact of ARNi â€œBeyond the Wallâ€•of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19. Frontiers in Cardiovascular Medicine, 2020, 7, 616564.	1.1	4
580	Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?. European Heart Journal, 2020, 41, 4232-4233.	1.0	4
581	Old and novel insights into emergency peripartum hysterectomy: a time-trend analysis. Archives of Gynecology and Obstetrics, 2020, 301, 1159-1165.	0.8	4
582	PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. European Heart Journal, 2021, 42, 1130-1131.	1.0	4
583	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. European Heart Journal, 2021, 42, 1458-1459.	1.0	4
584	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. European Heart Journal, 2021, 42, 2329-2330.	1.0	4
585	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. European Heart Journal, 2021, 42, 370-371.	1.0	4
586	Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats. , 0, .		4
587	Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination. Clinical Drug Investigation, 2012, , 1.	1.1	4
588	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. European Heart Journal, 2021, 42, 14-15.	1.0	4
589	Does Clinical Governance influence the quality of medical records?. Annali Dell'Istituto Superiore Di Sanita, 2018, 54, 104-108.	0.2	4
590	Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2000, 1, 96-103.	0.1	4
591	Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice. Internal and Emergency Medicine, 2022, 17, 645-654.	1.0	4
592	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. European Heart Journal, 2022, 43, 559-560.	1.0	4
593	Predictability of antihypertensive efficacy of selective Î²1 blockers. Clinical Pharmacology and Therapeutics, 1983, 34, 758-763.	2.3	3
594	Efficacy of Once-Daily Urapidil Treatment in Mild or Moderate Essential Hypertension Assessed by Ambulatory 24-Hour Blood Pressure Monitoring. Drugs, 1988, 35, 173-181.	4.9	3

#	Article	IF	Citations
595	Regulation of 11?? -hydroxylase cytochrome P450 expression by cholesterol in spontaneously hypertensive rats. Journal of Hypertension, 1995, 13, 1253-1258.	0.3	3
596	The ???ForLife??? Study. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 91-93.	1.0	3
597	Angiotensin receptor blockers and myocardial infarction: the importance of dosage. Journal of Hypertension, 2006, 24, 1681-1682.	0.3	3
598	Prevalence of â€˜Borderlineâ€™ Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 43-51.	1.0	3
599	Hyperbaric oxygen therapy in a case of cholesterol crystal embolization. American Journal of Emergency Medicine, 2011, 29, 694.e3-694.e6.	0.7	3
600	Is there any memory effect of blood pressure lowering in diabetes?. International Journal of Cardiology, 2011, 151, 384-385.	0.8	3
601	Olmesartan medoxomil for the treatment of hypertension in children and adolescents. Vascular Health and Risk Management, 2011, 7, 177.	1.0	3
602	Lack of Influence of the Androgen Receptor Gene CAG-Repeat Polymorphism on Clinical and Electrocardiographic Manifestations of the Brugada Syndrome in Man. Clinical Medicine Insights: Cardiology, 2012, 6, CMC.S10553.	0.6	3
603	Diagnosis and treatment of resistant hypertension. Blood Pressure, 2014, 23, 193-199.	0.7	3
604	An easy and reproducible parameter for the assessment of the pressure gradient in patients with aortic stenosis disease: A magnetic resonance study. Journal of Cardiology, 2015, 65, 369-376.	0.8	3
605	Angiotensin IIâ€“Linked Hypothesis to Understand the Advantage of the Coevolution of Hypertension and Malaria. Circulation Research, 2016, 119, 1046-1048.	2.0	3
606	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 255-263.	1.0	3
607	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. International Journal of Cardiology, 2019, 291, 105-111.	0.8	3
608	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 467-473.	1.0	3
609	An evolutionary rebus. Journal of Hypertension, 2019, 37, 1344-1346.	0.3	3
610	Effects of dual inhibition of reninâ€“angiotensinâ€“aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine, 2020, 15, 373-379.	1.0	3
611	To whom recommend intensive treatment for hypertension?. European Heart Journal Supplements, 2020, 22, E167-E172.	0.0	3
612	OUP accepted manuscript. European Heart Journal, 2021, 42, 4789-4790.	1.0	3

#	Article	IF	Citations
613	Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24â€‰h ambulatory blood pressure monitoring database. Journal of Human Hypertension, 2022, 36, 40-50.	1.0	3
614	A SPRINT towards tighter control of blood pressure in hypertension. European Heart Journal, 2021, 42, 3042-3043.	1.0	3
615	Global Cardiovascular Risk Management in Primary Prevention. Current Vascular Pharmacology, 2012, 10, 709-711.	0.8	3
616	Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 541-545.	1.0	3
617	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 105-113.	1.0	3
618	Myocarditis after BNT162b2 mRNA SARS-CoV-2 vaccine: low incidence and mild severity. European Heart Journal, 2022, , .	1.0	3
619	Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. Journal of Nephrology, 2007, 20 Suppl 12, S12-8.	0.9	3
620	Impact of a NDUFC2 Variant on the Occurrence of Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	3
621	Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy. Current Medical Research and Opinion, 2022, 38, 1673-1681.	0.9	3
622	The Reflex Control of Arginine-Vasopressin Release in Essential Hypertension. Clinical Science, 1981, 61, 145s-147s.	0.0	2
623	INVERTED RESPONSE OF ARGININE VASOPRESSIN TO POSTURAL CHANGE IN PATIENTS WITH ESSENTIAL HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 1982, 9, 95-100.	0.9	2
624	Haemodynamic and clinical effects of long-term treatment of essential hypertension with captopril. European Heart Journal, 1983, 4, 496-501.	1.0	2
625	Reversal of Left Ventricular Hypertrophy following Treatment with Beta-Blockers: Experience with Tertatolol. American Journal of Nephrology, 1986, 6, 94-99.	1.4	2
626	Effect of complete cardiac denervation on atrial natriuretic factor release in baboons. Journal of Surgical Research, 1992, 53, 43-47.	0.8	2
627	Role of angiotensin II AT 1 and AT 2 subtype receptors in the regulation of atrial natriuretic peptide expression in salt-restricted rats. Basic Research in Cardiology, 2000, 95, 64-69.	2.5	2
628	Antihypertensive effect and end-organ protection of flavonoids: some insights, more questions. Journal of Hypertension, 2002, 20, 1721-1724.	0.3	2
629	Evidence-Based Indications in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 1-7.	1.0	2
630	Treating Hypertension with Angiotensin II Receptor Blockers. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 9-15.	1.0	2

#	Article	IF	Citations
631	Similarities and Differences in Hypertension Guidelines. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 63-66.	1.0	2
632	Use of predictive markers to improve cardiovascular protection. Future Cardiology, 2007, 3, 447-456.	0.5	2
633	Letter by Conti and Volpe Regarding Article, â€œCardiac Troponin I but Not Cardiac Troponin T Induces Severe Autoimmune Inflammation in the Myocardiumâ€. Circulation, 2007, 115, e383; author reply e384.	1.6	2
634	High Blood Pressure & Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 1-3.	1.0	2
635	Effects of Olmesartan on Endothelial Function. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 221-227.	1.0	2
636	TRANSCEND Aftermath. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 1-6.	1.0	2
637	Letter by Assenza et al Regarding Article, â€œElectrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasiaâ€. Circulation, 2010, 121, e405; author reply e406.	1.6	2
638	Low-dose angiotensin receptor blockers as an alternative to ACE-inhibitors increase the risk of appropriate ICD interventions in heart failure. International Journal of Cardiology, 2010, 145, 522-524.	0.8	2
639	Impact of physiciansâ€™ age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. International Journal of Clinical Practice, 2011, 65, 649-657.	0.8	2
640	High natriuretic peptide levels and low DBP. Journal of Hypertension, 2014, 32, 2142-2143.	0.3	2
641	Cardiovascular Prevention: The Role of Second Generation of Nutraceuticals. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 155-157.	1.0	2
642	AT1Râ€“AT2R Cross Talk. , 2015, , 35-39.		2
643	Tpâ€“Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	0.8	2
644	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. Revista Portuguesa De Cardiologia, 2018, 37, 351.e1-351.e4.	0.2	2
645	The â€œhidden side of the moonâ€•in hypertension: When and why is dangerous low diastolic blood pressure?. International Journal of Cardiology, 2019, 276, 268-270.	0.8	2
646	Genes and hypertension: stepping into the secret through the arterial wall. European Heart Journal, 2020, 41, 3323-3324.	1.0	2
647	Systolic blood pressure target less than 120â€ŠmmHg: the â€˜Chariot Allegoryâ€™ in hypertension?. Journal of Hypertension, 2020, 38, 1462-1463.	0.3	2
648	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. European Heart Journal, 2020, 41, 3986-3987.	1.0	2

#	Article	IF	Citations
649	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 195-201.	1.0	2
650	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. European Heart Journal, 2021, 42, 1061-1062.	1.0	2
651	RELATIONSHIP BETWEEN DIURETIC RELATED HYPERURICEMIA AND CARDIOVASCULAR EVENTS: DATA FROM THE URRAH (URIC ACID RIGHT FOR HEART HEALTH) STUDY. Journal of Hypertension, 2021, 39, e45.	0.3	2
652	Role of induced pluripotent stem cells in diagnostic cardiology. World Journal of Stem Cells, 2021, 13, 331-341.	1.3	2
653	Unhealthy lifestyles mediate only a small proportion of the socioeconomic inequalitiesâ€™ impact on cardiovascular outcomes in US and UK adults: a call for action for social cardiology. European Heart Journal, 2021, 42, 2420-2421.	1.0	2
654	Hypertension Management and Control in Italy: A Real-World Survey in Elderly Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 425-426.	1.0	2
655	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. European Heart Journal, 2021, 42, 4518-4519.	1.0	2
656	Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients. Journal of Hypertension, 2021, 39, 169-180.	0.3	2
657	Implantable recorders and systematic atrial fibrillation detection do not outperform standard of care in stroke prevention in the LOOP study. European Heart Journal, 2022, 43, 261-262.	1.0	2
658	Breath tests sustainability in hospital settings: cost analysis and reimbursement in the Italian National Health System. European Review for Medical and Pharmacological Sciences, 2013, 17 Suppl 2, 99-104.	0.5	2
659	Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials. European Heart Journal, 2022, 43, 1700-1701.	1.0	2
660	Capturing the chance for pneumococcal vaccination in the hospital setting. Annali Dell'Istituto Superiore Di Sanita, 2017, 53, 291-298.	0.2	2
661	Nifedipine inhibits superoxide production induced by pulsatile stretch in human aortic endothelial cells. American Journal of Hypertension, 2000, 13, S34.	1.0	1
662	The gene encoding atrial natriuretic peptide and the risk of ischemic stroke in males. American Journal of Hypertension, 2002, 15, A12.	1.0	1
663	AT2-mediated vasorelaxation by angiotensin II in SHR chronically treated with losartan. American Journal of Hypertension, 2002, 15, A13.	1.0	1
664	Genetic Factors Underlying Impaired Endothelium-Dependent Vasorelaxation in the Stroke-Prone Spontaneously Hypertensive Rat. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 69-73.	1.0	1
665	Do COX-2 inhibitors really prevent hypertension and proteinuria? Another brick in the wall for the COX-2 inhibition and cardiovascular disease controversy. Journal of Hypertension, 2003, 21, 501-503.	0.3	1
666	A Novel Molecule of the Angiotensin II Receptor Blocker Class. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 79-89.	1.0	1

#	Article	IF	Citations
667	Adverse Effects of Statins. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 141???148.	1.0	1
668	Natriuretic Peptides. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 215-223.	1.0	1
669	Upcoming Challenges for Training in Cardiology. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 201-206.	1.0	1
670	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 17-22.	1.0	1
671	A New Option for Therapeutic Management of Patients with Cerebrovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 105-107.	1.0	1
672	Coronary artery fistula from the circumflex artery to the left atrium: invasive and non-invasive imaging techniques. Journal of Cardiovascular Medicine, 2008, 9, 320-322.	0.6	1
673	Cardiopulmonary exercise testing in heart failure: from ugly duckling to swan. Internal and Emergency Medicine, 2009, 4, 263-264.	1.0	1
674	A case of thrombolysis in acute pulmonary embolism with right atrial thrombus: comparing current and past guidelines. Internal and Emergency Medicine, 2009, 4, 497-500.	1.0	1
675	Aminoterminal natriuretic peptide as a determinant of PAI-1 levels in a sample of the adult male Italian population. Journal of Thrombosis and Haemostasis, 2011, 9, 1662-1663.	1.9	1
676	Shooting beyond score. Journal of Hypertension, 2012, 30, 1909-1910.	0.3	1
677	Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective. Expert Review of Cardiovascular Therapy, 2013, 11, 653-656.	0.6	1
678	Acetyltransferase gene non-derepressible 5 mediates hyperglycemia-induced endothelial oxidative stressin patients with type 2 diabetes. European Heart Journal, 2013, 34, P587-P587.	1.0	1
679	The lifespan determinant p66shc drives obesity-induced oxidative stress, mitochondrial dysfunction and vascular inflammation. European Heart Journal, 2013, 34, 781-781.	1.0	1
680	Impact of the Direct Angiotensin II Type 2 Receptor Stimulation on Renal Function. Hypertension, 2014, 64, 227-228.	1.3	1
681	An atypical clinical presentation of renovascular hypertension. International Journal of Cardiology, 2014, 177, e107-e110.	0.8	1
682	Erythropoiesisâ€stimulating agents in heart failure: leave it or reâ€take it?. European Journal of Heart Failure, 2015, 17, 1089-1090.	2.9	1
683	Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough?. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 189-190.	1.4	1
684	Chance for in-hospital pneumococcal vaccination. Analysis of discharge data from an Italian hospital. European Journal of Public Health, 2016, 26, .	0.1	1

#	Article	IF	Citations
685	Restrictive cardiomyopathy and pseudoxanthoma elasticum skin lesions. Journal of Cardiovascular Medicine, 2016, 17, e193-e195.	0.6	1
686	The Age of Nutraceuticals: Exploring New Therapeutic Targets. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 337-339.	1.0	1
687	Patient at intermediate cardiovascular risk. Journal of Cardiovascular Medicine, 2018, 19, e130-e132.	0.6	1
688	Calcium Channel Blockers for the Clinical Management of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 1-3.	1.0	1
689	Lifestyle and cardiovascular disease: Barefooting through the guidelines. International Journal of Cardiology, 2018, 263, 156-157.	0.8	1
690	Search of multiple markers of organ damage for better cardiovascular risk stratification in hypertension: Role of â€œSHATSâ€•syndrome in the clinical practice. International Journal of Cardiology, 2018, 263, 154-155.	0.8	1
691	Natriuretic Peptides. Updates in Hypertension and Cardiovascular Protection, 2019, , 87-100.	0.1	1
692	Electrocardiographic changes in focal takotsubo syndrome. Journal of Cardiovascular Medicine, 2019, 20, 783-786.	0.6	1
693	Aspirin in primary prevention. Journal of Hypertension, 2019, 37, 2298-2299.	0.3	1
694	Excess of dyslipidemia in low income countries: The case of Colombia in the PURE study. International Journal of Cardiology, 2019, 290, 152-153.	0.8	1
695	The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. European Heart Journal, 2020, 41, 4302-4303.	1.0	1
696	Could maternal ethnicity be a determinant of healthcare costs for birth assistance? Insights from a retrospective hospital-based study for the implementation of a woman-centered approach in obstetrics. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 223-229.	0.7	1
697	T2238C atrial natriuretic peptide gene variant and cardiovascular events in patients with atrial fibrillation: A substudy from the ATHERO-AF cohort. International Journal of Cardiology, 2021, 322, 245-249.	0.8	1
698	Iron heart. European Heart Journal, 2021, 42, 809-810.	1.0	1
699	Real-life appraisal on blood pressure targets achievement in adult outpatients at high cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 472-480.	1.1	1
700	Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factor. European Heart Journal, 2021, 42, 1197-1198.	1.0	1
701	Cryoblation as first-line treatment of new-onset atrial fibrillation?. European Heart Journal, 2021, 42, 1543-1544.	1.0	1
702	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 255-262.	1.0	1

#	Article	IF	Citations
703	A â€˜Once-and-Doneâ€™ Approach to the Lifelong Reduction of Elevated Cholesterol. European Heart Journal, 2021, 42, 3820-3821.	1.0	1
704	Exploring RNA biomarkers in patients with acute myocarditis. European Heart Journal, 2021, 42, 3425-3426.	1.0	1
705	An inflammatory ageing clock to detect cardiovascular and other age-related diseases: a new approach to preventive medicine. European Heart Journal, 2021, 42, 4296-4297.	1.0	1
706	Repurposing Cardio-Metabolic Drugs to Fight Covid19. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 419-423.	1.0	1
707	Angiotensinogen and Angiotensins. , 2019, , 483-489.		1
708	Follow-up, study design and outcome parameters. EuroIntervention, 2013, 9, R96-R100.	1.4	1
709	OUP accepted manuscript. European Heart Journal, 2021, 42, 4885-4886.	1.0	1
710	Angiotensin receptor blockers: clinical relevance and new opportunities. Hot Topics in Hypertension, 0, , .	1.0	1
711	VANISHing the progression of cardiac abnormalities in hypertrophic cardiomyopathy with early use of valsartan?. European Heart Journal, 2022, 43, 181-182.	1.0	1
712	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. European Heart Journal, 2022, 43, 448-449.	1.0	1
713	Blood pressure lowering drugs differ in their capacity to prevent type 2 diabetes. European Heart Journal, 2022, , .	1.0	1
714	Myocardial Infarction in Patients Without Cardiovascular Risk Factors. JACC: Cardiovascular Interventions, 2022, 15, 1176-1178.	1.1	1
715	Synthetic ANF Potentiates Bradycardic Baroreflex Response in the Rabbit. Journal of Cardiovascular Pharmacology, 1986, 8, 1314.	0.8	0
716	Cardiopulmonary receptors and coronary circulation. Journal of the Autonomic Nervous System, 1990, 30, S173-S177.	1.9	0
717	Long-term effects of felodipine in patients with mild heart failure treated chronically with enalapril: a randomized, placebo-controlled study. Current Therapeutic Research, 1998, 59, 288-306.	0.5	0
718	Genetic analysis of the endothelial-dependent impaired vasorelaxation in the stroke-prone spontaneously hypertensive rat: a candidate gene approach.. American Journal of Hypertension, 1999, 12, 197.	1.0	0
719	The Effect of the Menopause on Women at Risk of Heart Disease. The Journal of the British Menopause Society, 1999, 5, 30-35.	1.3	0
720	Biological relevance of a proANP molecular variant in human endothelial cells. American Journal of Hypertension, 2003, 16, A67.	1.0	0

#	Article	IF	Citations
721	Angiotensin Receptor Blockers. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 47-49.	1.0	0
722	Hypertension Surveys. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 157-158.	1.0	0
723	Head-to-Head Intervention Trials in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 1-4.	1.0	0
724	What Should We Expect from the Next Guidelines on Hypertension?. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 199-202.	1.0	0
725	Role of ANP gene on cardiac hypertrophy in essential hypertension. American Journal of Hypertension, 2005, 18, A84-A84.	1.0	0
726	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	1.0	0
727	The Apelin/APJ System. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 159-162.	1.0	0
728	Discovering a New Role for the Atrial Natriuretic Peptide: A Novel Risk Factor for Cardiovascular Diseases. Heart International, 2006, 2, 182618680600200.	0.4	0
729	Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension. Current Hypertension Reviews, 2007, 3, 196-202.	0.5	0
730	JustificaciÃ³n de la terapia combinada con IECA y bloqueadores de los canales de calcio en la hipertensiÃ³n. Hipertension, 2007, 24, 256-260.	0.0	0
731	The Role of Arterial Stiffness in Stratifying the Overall Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 89-97.	1.0	0
732	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 139-144.	1.0	0
733	Chronic AC-SDKP Administration Reduces Cardiac and Renal Perivascular Fibrosis in Diabetic Rats. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
734	Conventional and Tissue Doppler Evaluation of Systolic and Diastolic Function in a Cohort of Paediatric Obese Subjects. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
735	Impact of Diabetes and Impaired Glucose Tolerance (IGT) on Complications and Hospitalisation in Patients with Acute Coronary Syndrome. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
736	Impact of Gender on Left Ventricular Adaption to Chronic Pressure Overload in Hypertensive Adults with Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
737	Elevated B-Type Natriuretic Peptide Indicates Increased End-Diastolic Pressure in Patients with Mild-Moderate Heart Failure and Systolic Dysfunction: The AREA-IN-CHF Study. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
738	Peroxisome Proliferator-Activated Receptors Activator, Rosiglitazone, Improves Vascular Structure and Reduces Lipid Deposition in Atherosclerotic Mthfr Knock-Out Mice. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0

#	Article	IF	Citations
739	The Vasodilation at the Beginning of the Exercise in the Muscular Microcirculation is More Evident in the Repeated Exercise. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	1.0	0
740	Effort angina in a patient with advanced coronary artery disease. Role played by coronary angiography, Ivus and cardiac CT: case report. Cardiovascular Ultrasound, 2008, 6, 48.	0.5	0
741	Î²-Blockers and Diuretics in the Treatment of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 109-111.	1.0	0
742	1.10 Superiority of Apolipoproteins Compared to Non-HDL Cholesterol in Predicting the Presence of Coronary Disease in Hypertensive Patients with Ischemic Heart Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 180-180.	1.0	0
743	1.11 Prevalence of Metabolic Alterations In Hypertensive Patients with Stable vs Unstable Angina. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 181-181.	1.0	0
744	Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines. Current Hypertension Reviews, 2008, 4, 234-240.	0.5	0
745	The Myth of Janus. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 35-37.	1.0	0
746	ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY: HT.1.03. Journal of Hypertension, 2010, 28, e45-e46.	0.3	0
747	2009 SIPREC Consensus Document â€“ Executive Summary. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 237-247.	1.0	0
748	High Blood Pressure & Cardiovascular Prevention is now on MEDLINE. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 41.	1.0	0
749	Presenilin Mediated Ca2+ Changes and Protein Quality Control in Heart Failure. Journal of Cardiac Failure, 2011, 17, S1.	0.7	0
750	Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial. Clinical Investigation, 2011, 1, 605-610.	0.0	0
751	Network Meta-analysis of Heart Failure Prevention by Antihypertensive Drugsâ€”Reply. Archives of Internal Medicine, 2011, 171, 472.	4.3	0
752	Eplerenone works. Does it matter how?. Expert Review of Cardiovascular Therapy, 2012, 10, 131-133.	0.6	0
753	Omega-3 in Antiarrhythmic Therapy. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 199-200.	1.0	0
754	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	1.0	0
755	'QRS duration and QRS fractionation on surface electrocardiogram are markers of right ventricular dysfunction and atrialization in patients with Ebstein anomaly' [Eur Heart J 2012;34:191-200, doi:10.1093/eurheartj/ehs362]. European Heart Journal, 2013, 34, 624-624.	1.0	0
756	Invasive treatment strategy in elderly patients with non ST elevation acute coronary syndromes. A sensitivity analysis of a large monocentric retrospective study. European Heart Journal, 2013, 34, P422-P422.	1.0	0

#	Article	IF	Citations
757	Hyperglycemia-induced myocardial oxidative stress and inflammation persist despite optimal glycemic control: role of mitochondrial adaptor p66shc. European Heart Journal, 2013, 34, 1602-1602.	1.0	0
758	Adverse epigenetic remodelling of p66shc gene correlates with persistent endothelial dysfunction and oxidative stress in type 2 diabetics with optimal glycemic control. European Heart Journal, 2013, 34, 5927-5927.	1.0	0
759	Renin-angiotensin system blockers increase risk of angio-oedema. Evidence-Based Medicine, 2013, 18, e52-e52.	0.6	0
760	Prolyl-isomerase-1 (pin1) mediates hyperglycemia-induced oxidative stress, endothelial function and vascular inflammation: insights in patients with type 2 diabetes. European Heart Journal, 2013, 34, P3260-P3260.	1.0	0
761	Electrocardiographic features and clinical course of patients with hypertrophic cardiomyopathy and left ventricular apical aneurysm. European Heart Journal, 2013, 34, P1194-P1194.	1.0	0
762	Reducing therapeutic inertia to improve blood pressure control. Journal of Hypertension, 2014, 32, 988-989.	0.3	0
763	PP.27.11. Journal of Hypertension, 2015, 33, e369-e370.	0.3	0
764	In Memory of Professor John H. Laragh. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 197-197.	1.0	0
765	Combination Therapy for the Clinical Management of Hypertension. , 2015, , 887-902.		0
766	Managing hypertension after acute coronary syndrome. Journal of Hypertension, 2015, 33, 700-701.	0.3	0
767	Epigenetics in Cardiac Health and Disease225miR-218 and mi-R34a drive persistent myocardial oxidative stress by targeting chromatin remodelers DNMT3b and SIRT1: new mechanistic insights in diabetic cardiomyopathy226Effects of miRNAs modulated by endurance training on cardiomyocyte excitability227Differential transcriptome and microRNA expression signatures in the healthy heart (RV) Tj ETQq1 1 0.784314 rgBT /Over	1.8	0
768	[OP.8C.03] IMPROVED ENDOTHELIAL FUNCTION AND E-NOS EXPRESSION AND FUNCTION IN TRANSGLUTAMINASE-2 KNOCK-OUT MICE INFUSED WITH ANGIOTENSIN-II. Journal of Hypertension, 2016, 34, e102.	0.3	0
769	National Cross-Sectional Survey on Blood Pressure: A Gateway to a Better Appraisal of Hypertension in the Young. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 141-142.	1.0	0
770	Recurrence of acute coronary syndrome during inadeguate control of cardiovascular risk factors. Atherosclerosis, 2017, 263, e188-e189.	0.4	0
771	Gender differences in acute coronary syndromes: Do they count?. Atherosclerosis, 2017, 263, e193.	0.4	0
772	Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH). Atherosclerosis, 2017, 263, e246-e247.	0.4	0
773	[OP.3C.01] COMPARISON BETWEEN EUROPEAN SYSTEMATIC CORONARY RISK EVALUATION AND ITALIAN CUORE ALGORITHMS IN ADULT OUTPATIENTS FOLLOWED BY GENERAL PRACTITIONERS AND SPECIALISED CENTRES. Journal of Hypertension, 2017, 35, e30.	0.3	0
774	[OP.6A.06] PREVALENCE AND CLINICAL CHARACTERISTICS OF TRUE MASKED HYPERTENSION COMPARED TO REVERSE AND ISOLATED NOCTURNAL MASKED HYPERTENSION. Journal of Hypertension, 2017, 35, e56.	0.3	0

#	Article	IF	Citations
775	[PP.01.17] ADDING HYPERTENSION-RELATED MARKERS OF ORGAN DAMAGE TO RISK SCORE MODELS IMPROVES CARDIOVASCULAR RISK ASSESSMENT. Journal of Hypertension, 2017, 35, e97.	0.3	0
776	[PP.04.18] COMPARISON AMONG DIFFERENT ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY. Journal of Hypertension, 2017, 35, e116.	0.3	0
777	[PP.09.15] CHRONIC HEMODIALYSIS CONTRIBUTES TO INCREASED ARTERIAL STIFFNESS AND TO IMPAIRED DIASTOLIC FUNCTION IN PATIENTS WITH END-STAGE RENAL DISEASE AFTER SIXTY MONTHS OF TREATMENT. Journal of Hypertension, 2017, 35, e153.	0.3	0
778	[PP.04.30] PRESERVED CARDIOVASCULAR PERFORMANCE AND OPTIMAL HEART RATE CONTROL IN PATIENTS WITH POST-ISCHEMIC LEFT VENTRICULAR DYSFUNCTION TREATED WITH IVABRADINE FOR ONE YEAR. Journal of Hypertension, 2017, 35, e119.	0.3	0
779	Microbiological ascertainment in patients with pneumonia: is there room for improvement?. European Journal of Public Health, 2017, 27, .	0.1	0
780	Hypertension and social determinants in a cohort of migrants acceding an outpatient clinic in Rome. European Journal of Public Health, 2017, 27, .	0.1	0
781	TRANSGLUTAMINASE-2 CONTRIBUTES TO REACTIVE OXYGEN SPECIES PRODUCTION IN MICE INFUSED WITH ANGIOTENSIN-II. Journal of Hypertension, 2018, 36, e116.	0.3	0
782	1431Modulation of JunD by miR-494-3p causes intra-myocardial lipid accumulation and obesity cardiomyopathy: a study in mice and humans. European Heart Journal, 2018, 39, .	1.0	0
783	Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 351.e1-351.e4.	0.2	0
784	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
785	What's HIV got to do with cardiovascular disease?. International Journal of Cardiology, 2018, 265, 210-211.	0.8	0
786	P5403Platelet lncRNA and mRNA: unravelling the role of epigenetic modulation in acute coronary syndrome. European Heart Journal, 2019, 40, .	1.0	0
787	EPIGENETIC EFFECT OF DIABETES ON CODING AND NON-CODING PLATELET TRANSCRIPTOME IN ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 2019, 73, 55.	1.2	0
788	SERUM URIC ACID, INDEPENDENTLY OF ARTERIAL HYPERTENSION, PREDICTS FATAL HEART FAILURE IN A LARGE COHORT OF MEN AND WOMEN. SEARCH FOR A CUT-OFF VALUE. Journal of Hypertension, 2019, 37, e91.	0.3	0
789	PROGNOSTIC CUT-OFF VALUES OF SERUM URIC ACID ASSOCIATED WITH FATAL AND NON FATAL INCIDENT MYOCARDIAL INFARCTION INDEPENDENTLY OF ARTERIAL HYPERTENSION IN A LARGE COHORT. Journal of Hypertension, 2019, 37, e221.	0.3	0
790	How much drug-induced blood pressure reduction is effective and safe in heart failure?. Journal of Hypertension, 2019, 37, 1786-1787.	0.3	0
791	How to Improve Patientsâ€™ Adherence to Antihypertensive Therapy: A Simple Solution for a Big Trouble. American Journal of Hypertension, 2019, 32, 141-142.	1.0	0
792	Response to letter from Madias regarding our article â€œAdmission heart rate and in-hospital course of patients with Takotsubo syndromeâ€. International Journal of Cardiology, 2019, 274, 64.	0.8	0

#	Article	IF	Citations
793	Out-of-Hospital Cardiac Arrest: Handle With Careâ€“Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. European Heart Journal, 2020, 41, 4165-4166.	1.0	0
794	Vulnerable non-culprit coronary plaques: are they worth treating?. European Heart Journal, 2021, 42, 2233-2234.	1.0	0
795	Glycaemicindex: an emergent global silent killer for the heart. European Heart Journal, 2021, 42, 2727-2728.	1.0	0
796	Worsening of risk factor control in US diabetic patients: a call to action. European Heart Journal, 2021, 42, 3120-3121.	1.0	0
797	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. European Heart Journal, 2021, 42, 3902-3903.	1.0	0
798	Computed tomography coronary angiography in acute chest pain: an excellent diagnostic tool with poor added value on clinical outcomes. European Heart Journal, 2022, 43, 103-104.	1.0	0
799	Another STEP towards tighter control of blood pressure in the elderly. European Heart Journal, 2021, 42, 4715-4716.	1.0	0
800	Cerebrovascular prevention by angiotensin II receptor antagonists. , 2006, , 173-188.		0
801	Discovering a new role for the atrial natriuretic peptide: A novel risk factor for cardiovascular diseases. Heart International, 2006, 2, 78.	0.4	0
802	Nationwide Trends in Hospitalization and Surgical Treatment of Congenital and Infantile Cataract Among Italian Children 4 Years and Younger. Journal of Pediatric Ophthalmology and Strabismus, 2009, 46, 210-214.	0.3	0
803	Pathophysiological Mechanisms and Prognostic Significance of Renal Functional Impairment in Cardiac Patients. , 2010, , 189-203.		0
804	Involvement of Health Professionals: From the General Practitioner to the Hypertension Specialist and the Hypertension Center. , 2013, , 181-191.		0
805	Anaemia and heart failure: is there still a role for erythropoiesis-stimulating agents?. Turk Kardiyoloji Dernegi Arsivi, 2017, 45, 217-218.	0.6	0
806	Drugs may worsen blood pressure control: focus on the underestimated role of non-steroidal anti-inflammatory drugs. European Heart Journal, 2022, , .	1.0	0
807	OUP accepted manuscript. European Heart Journal, 2022, , .	1.0	0
808	The DISCHARGE trial: imaging a new strategy for the clinical management of stable chest pain?. European Heart Journal, 2022, , .	1.0	0
809	Detection of risk factors in childhood: a new perspective in cardiovascular prevention. European Heart Journal, 2022, , .	1.0	0
810	Treatment of mild hypertension improves pregnancy outcomes. European Heart Journal, 2022, , .	1.0	0

#	Article	IF	Citations
811	Long lasting effects of renal denervation: lights and shadows of the SPYRAL HTN-ON MED 3-year follow-up. European Heart Journal, 0, , .	1.0	0
812	The UK TAVI trial: an independent, pragmatic study extending the evidence for the treatment of symptomatic severe aortic stenosis. European Heart Journal, 0, , .	1.0	0
813	Diastolic Blood Pressure Levels and Cardiovascular Risk in Elderly Women: The Need for a Personalized Approach. American Journal of Hypertension, 0, , .	1.0	0